Gastric Cancer: Pathobiology and Therapeutics

Abstract

Gastric cancer (GC) remains a formidable global health challenge, characterized by pronounced molecular heterogeneity, late-stage diagnosis, and limited durable responses to existing therapies. This review synthesizes recent advances in GC research through an integrated, multidisciplinary lens, spanning tumor biology, microenvironmental dynamics, and therapeutic innovation. We first consolidate updated histopathological and molecular classification systems, highlighting oncogenic programs that underpin GC development, including Hippo-YAP signaling and emerging neural–stem cell interactions. We then examine the immunosuppressive tumor microenvironment, emphasizing the dynamic crosstalk among tumor-associated macrophages, regulatory T cells, tertiary lymphoid structures, and cancer-associated fibroblasts that collectively drive metastatic dissemination and therapeutic resistance. Emerging biomarker-guided strategies, including CLDN18.2-targeted therapies, dual immune checkpoint blockade, and engineered cellular therapies, are critically discussed alongside rational combination approaches designed to overcome resistance. Beyond canonical paradigms, we highlight transformative frontiers, such as cancer neuroscience, microbiome-driven immune modulation, and spatially resolved multiomics technologies, that enable high-resolution mapping of cellular interactions. Finally, we critically assess translational barriers, including organ-specific metastatic tropism and resistance evolution, and propose that the convergence of deep molecular profiling, neural-immune modulation, and AI-enabled computational oncology will be central to advancing precision medicine for GC. This integrated framework aims to accelerate the development of mechanism-based combination therapies.

Keywords

gastric cancer / immunotherapy / molecular classification / neural regulation / targeted therapy / tumor microenvironment

References

[1] R. Kim, M. An, and H. Lee, “Early Tumor-Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer,” Cancer Discovery 12, no. 4 (2022): 984–1001.

[2] K. G. Yeoh and P. Tan, “Mapping the Genomic Diaspora of Gastric Cancer,” Nature Reviews Cancer 22, no. 2 (2021): 71–84.

[3] Y. Tanaka, F. Chiwaki, S. Kojima, et al., “Multi-Omic Profiling of Peritoneal Metastases in Gastric Cancer Identifies Molecular Subtypes and Therapeutic Vulnerabilities,” Nature Cancer 2, no. 9 (2021): 962–977.

[4] Q. Zhao, R. Huang, C. Wang, et al., “Dissecting Genetic and Immune Drivers of Heterogeneous Responses to Neoadjuvant Immunochemotherapy in Gastric Cancer,” Cancer Cell 44, no. 4 (2026): 809–830.

[5] A. Huber, A. H. Allam, C. Dijkstra, et al., “Mutant TP53 Switches Therapeutic Vulnerability During Gastric Cancer Progression Within Interleukin-6 Family Cytokines,” Cell Reports 43, no. 8 (2024): 114616.

[6] S. H. Lee, D. Lee, J. Choi, et al., “Spatial Dissection of Tumour Microenvironments in Gastric Cancers Reveals the Immunosuppressive Crosstalk Between CCL2+ Fibroblasts and STAT3-Activated Macrophages,” Gut 74, no. 5 (2025): 714–727.

[7] H. Chen, C. Jing, L. Shang, et al., “Molecular Characterization and Clinical Relevance of Metabolic Signature Subtypes in Gastric Cancer,” Cell Reports 43, no. 7 (2024): 114424.

[8] E. N. Baruch, F. O. Gleber-Netto, P. Nagarajan, et al., “Cancer-Induced Nerve Injury Promotes Resistance to Anti-PD-1 Therapy,” Nature 646, no. 8084 (2025): 462–473.

[9] X. Zhi, F. Wu, J. Qian, et al., “Nociceptive Neurons Promote Gastric Tumour Progression via a CGRP-RAMP1 Axis,” Nature 640, no. 8059 (2025): 802–810.

[10] J. Machlowska, J. Baj, M. Sitarz, R. Maciejewski, and R. Sitarz, “Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies,” International Journal of Molecular Sciences 21, no. 11 (2020): 4012.

[11] E. C. Smyth, M. Nilsson, H. I. Grabsch, N. C. van Grieken, and F. Lordick, “Gastric Cancer,” Lancet 396, no. 10251 (2020): 635–648.

[12] N. Y. Chia and P. Tan, “Molecular Classification of Gastric Cancer,” Annals of Oncology 27, no. 5 (2016): 763–769.

[13] T. Yasuda and Y. A. Wang, “Gastric Cancer Immunosuppressive Microenvironment Heterogeneity: Implications for Therapy Development,” Trends in Cancer 10, no. 7 (2024): 627–642.

[14] Z. Song, Y. Wu, J. Yang, D. Yang, and X. Fang, “Progress in the Treatment of Advanced Gastric Cancer,” Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine 39, no. 7 (2017): 1010428317714626.

[15] H. Sung, J. Ferlay, R. L. Siegel, et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 71, no. 3 (2021): 209–249.

[16] G. Luo, Y. Zhang, P. Guo, L. Wang, Y. Huang, and K. Li, “Global Patterns and Trends in Stomach Cancer Incidence: Age, Period and Birth Cohort Analysis,” International Journal of Cancer 141, no. 7 (2017): 1333–1344.

[17] E. Van Cutsem, X. Sagaert, B. Topal, K. Haustermans, and H. Prenen, “Gastric Cancer,” Lancet 388, no. 10060 (2016): 2654–2664.

[18] A. E. Russo and V. E. Strong, “Gastric Cancer Etiology and Management in Asia and the West,” Annual Review of Medicine 70 (2019): 353–367.

[19] V. E. Strong, K. Y. Song, C. H. Park, et al., “Comparison of Gastric Cancer Survival Following R0 Resection in the United States and Korea Using an Internationally Validated Nomogram,” Annals of surgery 251, no. 4 (2010): 640–646.

[20] H. J. Chon, W. J. Hyung, C. Kim, et al., “Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-Volume Center in Asia,” Annals of Surgery 265, no. 5 (2017): 946–953.

[21] P. Tan and K. G. Yeoh, “Genetics and Molecular Pathogenesis of Gastric Adenocarcinoma,” Gastroenterology 149, no. 5 (2015): 1153–1162.e3.

[22] S. K. Clinton, E. L. Giovannucci, and S. D. Hursting, “The World Cancer Research Fund/American Institute for Cancer Research Third Expert Report on Diet, Nutrition, Physical Activity, and Cancer: Impact and Future Directions,” Journal of Nutrition 150, no. 4 (2020): 663–671.

[23] M. Cisło, A. A. Filip, G. J. Arnold Offerhaus, et al., “Distinct Molecular Subtypes of Gastric Cancer: From Laurén to Molecular Pathology,” Oncotarget 9, no. 27 (2018): 19427–19442.

[24] R. M. Peek and M. J. Blaser, “Helicobacter pylori and Gastrointestinal Tract Adenocarcinomas,” Nature Reviews Cancer 2, no. 1 (2002): 28–37.

[25] M. A. Shah, “Update on Metastatic Gastric and Esophageal Cancers,” Journal of Clinical Oncology 33, no. 16 (2015): 1760–1769.

[26] J. K. Y. Hooi, W. Y. Lai, W. K. Ng, et al., “Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis,” Gastroenterology 153, no. 2 (2017): 420–429.

[27] M. Kidd, A. J. Lastovica, J. C. Atherton, and J. A. Louw, “Heterogeneity in the Helicobacter pylori vacA and cagA Genes: Association With Gastroduodenal Disease in South Africa?,” Gut 45, no. 4 (1999): 499–502.

[28] F. Kamangar, S. M. Dawsey, M. J. Blaser, et al., “Opposing Risks of Gastric Cardia and Noncardia Gastric Adenocarcinomas Associated With Helicobacter pylori Seropositivity,” Journal of the National Cancer Institute 98, no. 20 (2006): 1445–1452.

[29] J. Koshiol, W. Q. Wei, A. R. Kreimer, et al., “The Gastric Cardia Is Not a Target for Human Papillomavirus-Induced Carcinogenesis,” Cancer Epidemiology, Biomarkers & Prevention 19, no. 4 (2010): 1137–1139.

[30] H. J. Song, A. Srivastava, J. Lee, et al., “Host Inflammatory Response Predicts Survival of Patients With Epstein-Barr Virus-Associated Gastric Carcinoma,” Gastroenterology 139, no. 1 (2010): 84–92 e2.

[31] G. Maconi, G. Manes, and G. B. Porro, “Role of Symptoms in Diagnosis and Outcome of Gastric Cancer,” World Journal of Gastroenterology 14, no. 8 (2008): 1149–1155.

[32] N. Ikoma, J. H. Lee, M. S. Bhutani, et al., “Preoperative Accuracy of Gastric Cancer Staging in Patient Selection for Preoperative Therapy: Race May Affect Accuracy of Endoscopic Ultrasonography,” Journal of Gastrointestinal Oncology 8, no. 6 (2017): 1009–1017.

[33] S. S. Joshi and B. D. Badgwell, “Current Treatment and Recent Progress in Gastric Cancer,” CA: A Cancer Journal for Clinicians 71, no. 3 (2021): 264–279.

[34] P. Lauren, “The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma,” Acta Pathologica et Microbiologica Scandinavica 64 (1965): 19.

[35] G. Tamura, J. Yin, S. Wang, et al., “E-Cadherin Gene Promoter Hypermethylation in Primary Human Gastric Carcinomas,” Journal of the National Cancer Institute 92 (2000): 5.

[36] H. Sakamoto, K. Yoshimura, N. Saeki, et al., “Genetic Variation in PSCA Is Associated With Susceptibility to Diffuse-type Gastric Cancer,” Nature Genetics 40, no. 6 (2008): 730–740.

[37] M. Kakiuchi, T. Nishizawa, H. Ueda, et al., “Recurrent Gain-of-Function Mutations of RHOA in Diffuse-Type Gastric Carcinoma,” Nature Genetics 46, no. 6 (2014): 583–587.

[38] K. Wang, S. T. Yuen, J. Xu, et al., “Whole-Genome Sequencing and Comprehensive Molecular Profiling Identify New Driver Mutations in Gastric Cancer,” Nature Genetics 46, no. 6 (2014): 573–582.

[39] Z. Lei, I. B. Tan, K. Das, et al., “Identification of Molecular Subtypes of Gastric Cancer With Different Responses to PI3-Kinase Inhibitors and 5-Fluorouracil,” Gastroenterology 145, no. 3 (2013): 554–565.

[40] K. Wang, J. Kan, S. T. Yuen, et al., “Exome Sequencing Identifies Frequent Mutation of ARID1A in Molecular Subtypes of Gastric Cancer,” Nature Genetics 43, no. 12 (2011): 1219–1223.

[41] C. Boger, S. Kruger, H. M. Behrens, et al., “Epstein-Barr Virus-Associated Gastric Cancer Reveals Intratumoral Heterogeneity of PIK3CA Mutations,” Annals of Oncology 28, no. 5 (2017): 1005–1014.

[42] Cancer Genome Atlas Research N. Comprehensive Molecular Characterization of Gastric Adenocarcinoma. Nature 2014; 513(7517): 202–209.

[43] F. Lordick and Y. Y. Janjigian, “Clinical Impact of Tumour Biology in the Management of Gastroesophageal Cancer,” Nature Reviews Clinical Oncology 13, no. 6 (2016): 348–360.

[44] H. H. N. Yan, H. C. Siu, S. Law, et al., “A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening,” Cell Stem Cell 23, no. 6 (2018): 882–897 e11.

[45] Y. Huang, S. Chen, Y. Yao, et al., “Ovotransferrin Alleviated Acute Gastric Mucosal Injury in BALB/c Mice Caused by Ethanol,” Food & Function 14, no. 1 (2023): 305–318.

[46] P. Correa and M. B. Piazuelo, “The Gastric Precancerous Cascade,” Journal of Digestive Diseases 13, no. 1 (2012): 2–9.

[47] Y. Zhao, Z. Deng, Z. Ma, et al., “Expression Alteration and Dysfunction of Ion Channels/Transporters in the Parietal Cells Induces Gastric Diffused Mucosal Injury,” Biomedicine & Pharmacotherapy 148 (2022): 112660.

[48] Z. Deng, J. Zhu, Z. Ma, et al., “The Mechanisms of Gastric Mucosal Injury: Focus on Initial Chief Cell Loss as a Key Target,” Cell Death Discovery 9, no. 1 (2023): 29.

[49] V. G. Weis and J. R. Goldenring, “Current Understanding of SPEM and Its Standing in the Preneoplastic Process,” Gastric Cancer 12, no. 4 (2009): 189–197.

[50] S. C. Shah, S. Gupta, D. Li, D. Morgan, R. A. Mustafa, and A. J. Gawron, “Spotlight: Gastric Intestinal Metaplasia,” Gastroenterology 158, no. 3 (2020): 704.

[51] Y. Hong, C. Staniorski, D. Pollack, and S. Evans, “Doxycycline-Induced Gastric Perforation,” American Surgeon 89, no. 11 (2023): 4926–4928.

[52] L. Du, F. Gao, and J. Zhang, “Effect of Weikang Capsule () on Aspirin-Related Gastric and Small Intestinal Mucosal Injury,” Chinese Journal of Integrative Medicine 27, no. 8 (2021): 621–625.

[53] J. Valle, M. Kekki, P. Sipponen, T. Ihamaki, and M. Siurala, “Long-Term Course and Consequences of Helicobacter pylori Gastritis. Results of a 32-Year Follow-Up Study,” Scandinavian Journal of Gastroenterology 31, no. 6 (1996): 546–550.

[54] H. M. Algood and T. L. Cover, “Helicobacter pylori Persistence: An Overview of Interactions Between H. pylori and Host Immune Defenses,” Clinical Microbiology Reviews 19, no. 4 (2006): 597–613.

[55] V. Camilo, T. Sugiyama, and E. Touati, “Pathogenesis of Helicobacter pylori Infection,” Helicobacter 22, no. suppl 1 (2017): 449–490.

[56] G. N. Borlace, S. J. Keep, M. J. Prodoehl, H. F. Jones, R. N. Butler, and D. A. Brooks, “A Role for Altered Phagosome Maturation in the Long-Term Persistence of Helicobacter pylori Infection,” American Journal of Physiology Gastrointestinal and Liver Physiology 303, no. 2 (2012): G169–G179.

[57] T. Ito, D. Kobayashi, K. Uchida, et al., “Helicobacter pylori Invades the Gastric Mucosa and Translocates to the Gastric Lymph Nodes,” Laboratory Investigation 88, no. 6 (2008): 664–681.

[58] D. G. Lee, H. S. Kim, Y. S. Lee, et al., “Helicobacter pylori CagA Promotes Snail-Mediated Epithelial-Mesenchymal Transition by Reducing GSK-3 Activity,” Nature Communications 5 (2014): 4423.

[59] D. Mueller, N. Tegtmeyer, S. Brandt, et al., “c-Src and c-Abl Kinases Control Hierarchic Phosphorylation and Function of the CagA Effector Protein in Western and East Asian Helicobacter pylori Strains,” Journal of Clinical Investigation 122, no. 4 (2012): 1553–1566.

[60] I. Saadat, H. Higashi, C. Obuse, et al., “Helicobacter pylori CagA Targets PAR1/MARK Kinase to Disrupt Epithelial Cell Polarity,” Nature 447, no. 7142 (2007): 330–333.

[61] H. Higashi, R. Tsutsumi, S. Muto, et al., “SHP-2 Tyrosine Phosphatase as an Intracellular Target of Helicobacter pylori CagA Protein,” Science 295, no. 5555 (2002): 683–686.

[62] I. O. Lee, J. H. Kim, Y. J. Choi, et al., “Helicobacter pylori CagA Phosphorylation Status Determines the gp130-Activated SHP2/ERK and JAK/STAT Signal Transduction Pathways in Gastric Epithelial Cells,” Journal of Biological Chemistry 285, no. 21 (2010): 16042–16050.

[63] T. Han, X. Jing, J. Bao, et al., “H. pylori Infection Alters Repair of DNA Double-Strand Breaks via SNHG17,” Journal of Clinical Investigation 130, no. 7 (2020): 3901–3918.

[64] L. P. Gong, J. N. Chen, M. Dong, et al., “Epstein-Barr Virus-Derived Circular RNA LMP2A Induces Stemness in EBV-Associated Gastric Cancer,” EMBO Reports 21, no. 10 (2020): e49689.

[65] M. D. Radyk, J. Burclaff, S. G. Willet, and J. C. Mills, “Metaplastic Cells in the Stomach Arise, Independently of Stem Cells, via Dedifferentiation or Transdifferentiation of Chief Cells,” Gastroenterology 154, no. 4 (2018): 839-843 e2.

[66] B. Caldwell, A. R. Meyer, J. A. Weis, A. C. Engevik, and E. Choi, “Chief Cell Plasticity Is the Origin of Metaplasia Following Acute Injury in the Stomach Mucosa,” Gut 71, no. 6 (2022): 1068–1077.

[67] E. Teal, M. Dua-Awereh, S. T. Hirshorn, and Y. Zavros, “Role of Metaplasia During Gastric Regeneration,” American Journal of Physiology. Cell Physiology 319, no. 6 (2020): C947–C954.

[68] N. Ogasawara, T. Tsukamoto, T. Mizoshita, et al., “RUNX3 Expression Correlates With Chief Cell Differentiation in Human Gastric Cancers,” Histology and Histopathology 24, no. 1 (2009): 31–40.

[69] K. Ito, K. I. Inoue, S. C. Bae, and Y. Ito, “Runx3 Expression in Gastrointestinal Tract Epithelium: Resolving the Controversy,” Oncogene 28, no. 10 (2009): 1379–1384.

[70] M. Leushacke, S. H. Tan, A. Wong, et al., “Lgr5-Expressing Chief Cells Drive Epithelial Regeneration and Cancer in the Oxyntic Stomach,” Nature Cell Biology 19, no. 7 (2017): 774–786.

[71] G. Kauffman, “Aspirin-Induced Gastric Mucosal Injury: Lessons Learned From Animal Models,” Gastroenterology 96, no. 2 pt 2 suppl (1989): 606–614.

[72] X. Chen, Y. Zhao, K. Liu, et al., “Lycopene Aggravates Acute Gastric Injury Induced by Ethanol,” Frontiers in Nutrition 8 (2021): 697879.

[73] D. Q. Zhao, H. Xue, and H. J. Sun, “Nervous Mechanisms of Restraint Water-Immersion Stress-Induced Gastric Mucosal Lesion,” World Journal of Gastroenterology 26, no. 20 (2020): 2533–2549.

[74] H. Sun, P. Zhao, W. Liu, L. Li, H. Ai, and X. Ma, “Ventromedial Hypothalamic Nucleus in Regulation of Stress-Induced Gastric Mucosal Injury in Rats,” Scientific Reports 8, no. 1 (2018): 10170.

[75] F. Fan, M. Yang, X. Geng, X. Ma, and H. Sun, “Effects of Restraint Water-Immersion Stress-Induced Gastric Mucosal Damage on Astrocytes and Neurons in the Nucleus Raphe Magnus of Rats via the ERK1/2 Signaling Pathway,” Neurochemical Research 44, no. 8 (2019): 1841–1850.

[76] R. J. Huang and M. C. Camargo, “An International Classification of Diseases Code for Gastric Intestinal Metaplasia: An Opportunity for Gastric Cancer Prevention,” Lancet Gastroenterology & Hepatology 9, no. 3 (2024): 201–202.

[77] M. Banks, D. Graham, M. Jansen, et al., “British Society of Gastroenterology Guidelines on the Diagnosis and Management of Patients at Risk of Gastric Adenocarcinoma,” Gut 68, no. 9 (2019): 1545–1575.

[78] A. R. Meyer and J. R. Goldenring, “Injury, Repair, Inflammation and Metaplasia in the Stomach,” Journal de Physiologie 596, no. 17 (2018): 3861–3867.

[79] T. Sugimura, N. Matsukura, and S. Sato, “Intestinal Metaplasia of the Stomach as a Precancerous Stage,” IARC Scientific Publications no. 39 (1982): 515–530.

[80] J. Drnovsek, M. Homan, N. Zidar, and L. M. Smid, “Pathogenesis and Potential Reversibility of Intestinal Metaplasia—A Milestone in Gastric Carcinogenesis,” Radiology and Oncology 58, no. 2 (2024): 186–195.

[81] V. Giroux and A. K. Rustgi, “Metaplasia: Tissue Injury Adaptation and a Precursor to the Dysplasia-Cancer Sequence,” Nature Reviews Cancer 17, no. 10 (2017): 594–604.

[82] Y. Liang, Y. Yang, R. Nong, et al., “Do Atrophic Gastritis and Intestinal Metaplasia Reverse After Helicobacter pylori Eradication?,” Helicobacter 29, no. 1 (2024): e13042.

[83] B. C. Wong, S. K. Lam, W. M. Wong, et al., “Helicobacter pylori Eradication to Prevent Gastric Cancer in a High-Risk Region of China: A Randomized Controlled Trial,” JAMA 291, no. 2 (2004): 187–194.

[84] H. N. Chen, Z. Wang, X. Li, and Z. G. Zhou, “Helicobacter pylori Eradication Cannot Reduce the Risk of Gastric Cancer in Patients With Intestinal Metaplasia and Dysplasia: Evidence From a Meta-Analysis,” Gastric Cancer 19, no. 1 (2016): 166–175.

[85] D. B. Stairs, J. Kong, and J. P. Lynch, “Cdx Genes, Inflammation, and the Pathogenesis of Intestinal Metaplasia,” Progress in Molecular Biology and Translational Science 96 (2010): 231–270.

[86] R. J. Guo, E. R. Suh, and J. P. Lynch, “The Role of Cdx Proteins in Intestinal Development and Cancer,” Cancer Biology & Therapy 3, no. 7 (2004): 593–601.

[87] M. Tatematsu, T. Tsukamoto, and K. Inada, “Stem Cells and Gastric Cancer: Role of Gastric and Intestinal Mixed Intestinal Metaplasia,” Cancer Science 94, no. 2 (2003): 135–141.

[88] Y. Fujii, K. Yoshihashi, H. Suzuki, et al., “CDX1 Confers Intestinal Phenotype on Gastric Epithelial Cells via Induction of Stemness-Associated Reprogramming Factors SALL4 and KLF5,” PNAS 109, no. 50 (2012): 20584–20589.

[89] H. Lickert, C. Domon, G. Huls, et al., “Wnt/(Beta)-Catenin Signaling Regulates the Expression of the Homeobox Gene Cdx1 in Embryonic Intestine,” Development 127, no. 17 (2000): 3805–3813.

[90] H. Kinoshita, Y. Hirata, H. Nakagawa, et al., “Interleukin-6 Mediates Epithelial-Stromal Interactions and Promotes Gastric Tumorigenesis,” PLoS ONE 8, no. 4 (2013): e60914.

[91] X. Liang, W. Du, L. Huang, et al., “Helicobacter pylori Promotes Gastric Intestinal Metaplasia Through Activation of IRF3-Mediated Kynurenine Pathway,” Cell Communication and Signaling 21, no. 1 (2023): 141.

[92] A. Shiotani, H. Iishi, N. Uedo, et al., “Evidence That Loss of Sonic Hedgehog Is an Indicator of Helicobater pylori-Induced Atrophic Gastritis Progressing to Gastric Cancer,” American Journal of Gastroenterology 100, no. 3 (2005): 581–587.

[93] H. Mutoh, H. Hayakawa, M. Sashikawa, H. Sakamoto, and K. Sugano, “Direct Repression of Sonic Hedgehog Expression in the Stomach by Cdx2 Leads to Intestinal Transformation,” Biochemical Journal 427, no. 3 (2010): 423–434.

[94] E. C. Smyth, M. Nilsson, H. I. Grabsch, N. C. T. van Grieken, and F. Lordick, “Gastric Cancer,” Lancet 396, no. 10251 (2020): 635–648.

[95] D. Hanahan, “Hallmarks of Cancer: New Dimensions,” Cancer Discovery 12, no. 1 (2022): 31–46.

[96] N. Grunberg, M. Pevsner-Fischer, T. Goshen-Lago, et al., “Cancer-Associated Fibroblasts Promote Aggressive Gastric Cancer Phenotypes via Heat Shock Factor 1-Mediated Secretion of Extracellular Vesicles,” Cancer Research 81, no. 7 (2021): 1639–1653.

[97] H.-T. Liu, S. Liu, L. Liu, R.-R. Ma, and P. Gao, “EGR1-Mediated Transcription of lncRNA-HNF1A-AS1 Promotes Cell Cycle Progression in Gastric Cancer,” Cancer Research 78, no. 20 (2018): 5877–5890.

[98] Y. Tang, G. Fang, F. Guo, et al., “Selective Inhibition of STRN3-Containing PP2A Phosphatase Restores Hippo Tumor-Suppressor Activity in Gastric Cancer,” Cancer Cell 38, no. 1 (2020): 115-128 e9.

[99] L. An, P. Nie, M. Chen, et al., “MST4 kinase Suppresses Gastric Tumorigenesis by Limiting YAP Activation via a Non-Canonical Pathway,” Journal of Experimental Medicine 217, no. 6 (2020): e20191817–e20191843.

[100] A. Higashimori, Y. Dong, Y. Zhang, et al., “Forkhead Box F2 Suppresses Gastric Cancer Through a Novel FOXF2-IRF2BPL-Beta-Catenin Signaling Axis,” Cancer Research 78, no. 7 (2018): 1643–1656.

[101] J. M. Kang, S. Park, S. J. Kim, et al., “KIAA1324 Suppresses Gastric Cancer Progression by Inhibiting the Oncoprotein GRP78,” Cancer Research 75, no. 15 (2015): 3087–3097.

[102] R. Xie, J. Xu, Y. Xiao, et al., “Calcium Promotes Human Gastric Cancer via a Novel Coupling of Calcium-Sensing Receptor and TRPV4 Channel,” Cancer Research 77, no. 23 (2017): 6499–6512.

[103] D. Wang, C. Xu, W. Yang, et al., “E3 ligase RNF167 and Deubiquitinase STAMBPL1 Modulate mTOR and Cancer Progression,” Molecular Cell 82, no. 4 (2022): 770-784 e9.

[104] M. E. Bahar, H. J. Kim, and D. R. Kim, “Targeting the RAS/RAF/MAPK Pathway for Cancer Therapy: From Mechanism to Clinical Studies,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 455.

[105] G. Li, Z. Wang, J. Ye, et al., “Uncontrolled Inflammation Induced by AEG-1 Promotes Gastric Cancer and Poor Prognosis,” Cancer Research 74, no. 19 (2014): 5541–5552.

[106] J. T. Low, M. Christie, M. Ernst, et al., “Loss of NFKB1 Results in Expression of Tumor Necrosis Factor and Activation of Signal Transducer and Activator of Transcription 1 to Promote Gastric Tumorigenesis in Mice,” Gastroenterology 159, no. 4 (2020): 1444–1458 e15.

[107] T. L. Putoczki, S. Thiem, A. Loving, et al., “Interleukin-11 Is the Dominant IL-6 Family Cytokine During Gastrointestinal Tumorigenesis and Can be Targeted Therapeutically,” Cancer Cell 24, no. 2 (2013): 257–271.

[108] H. Tye, L. Kennedy Catherine, and M. Najdovska, “STAT3-Driven Upregulation of TLR2 Promotes Gastric Tumorigenesis Independent of Tumor Inflammation,” Cancer Cell 22, no. 4 (2012): 466–478.

[109] M. Soutto, Z. Chen, A. A. Bhat, et al., “Activation of STAT3 Signaling Is Mediated by TFF1 Silencing in Gastric Neoplasia,” Nature Communications 10, no. 1 (2019): 3039.

[110] S. J. Hagen, L. H. Ang, Y. Zheng, et al., “Loss of Tight Junction Protein Claudin 18 Promotes Progressive Neoplasia Development in Mouse Stomach,” Gastroenterology 155, no. 6 (2018): 1852–1867.

[111] J. Tsihlias, L. Kapusta, and J. Slingerland, “The Prognostic Significance of Altered Cyclin-Dependent Kinase Inhibitors in Human Cancer,” Annual Review of Medicine 50 (1999): 401–423.

[112] H. Y. Xu, W. L. Xu, L. Q. Wang, M. B. Chen, and H. L. Shen, “Relationship Between p53 Status and Response to Chemotherapy in Patients With Gastric Cancer: A Meta-Analysis,” PLoS ONE 9, no. 4 (2014): e95371.

[113] Y. Takano, Y. Kato, P. J. van Diest, M. Masuda, H. Mitomi, and I. Okayasu, “Cyclin D2 Overexpression and Lack of p27 Correlate Positively and Cyclin E Inversely With a Poor Prognosis in Gastric Cancer Cases,” American Journal of Pathology 156, no. 2 (2000): 585–594.

[114] S. P. Singh, J. Lipman, H. Goldman, et al., “Loss or Altered Subcellular Localization of p27 in Barrett's Associated Adenocarcinoma,” Cancer Research 58, no. 8 (1998): 1730–1735.

[115] M. Mori, K. Mimori, T. Shiraishi, et al., “p27 Expression and Gastric Carcinoma,” Nature Medicine 3, no. 6 (1997): 593.

[116] S. Jiao, J. Guan, M. Chen, et al., “Targeting IRF3 as a YAP Agonist Therapy Against Gastric Cancer,” Journal of Experimental Medicine 215, no. 2 (2018): 699–718.

[117] J. Ju, H. Zhang, M. Lin, et al., “The Alanyl-tRNA Synthetase AARS1 Moonlights as a Lactyltransferase to Promote YAP Signaling in Gastric Cancer,” Journal of Clinical Investigation 134, no. 10 (2024): e174587.

[118] F. Wen, Y. Han, H. Zhang, et al., “Epstein-Barr Virus Infection Upregulates Extracellular OLFM4 to Activate YAP Signaling During Gastric Cancer Progression,” Nature Communications 15, no. 1 (2024): 10543.

[119] Z. Cao, L. An, Y. Han, S. Jiao, and Z. Zhou, “The Hippo Signaling Pathway in Gastric Cancer,” Acta Biochimica et Biophysica Sinica (Shanghai) 55, no. 6 (2023): 893–903.

[120] Y. Tang, F. Chen, G. Fang, et al., “A Cofactor-Induced Repressive Type of Transcription Factor Condensation Can be Induced by Synthetic Peptides to Suppress Tumorigenesis,” EMBO Journal 43, no. 22 (2024): 5586–5612.

[121] L. An, Z. Cao, P. Nie, et al., “Combinatorial Targeting of Hippo-STRIPAK and PARP Elicits Synthetic Lethality in Gastrointestinal Cancers,” Journal of Clinical Investigation 132, no. 9 (2022): e155468.

[122] A. J. Levine, “p53, the Cellular Gatekeeper for Growth and Division,” Cell 88, no. 3 (1997): 323–331.

[123] C. M. Fenoglio-Preiser, J. Wang, G. N. Stemmermann, and A. Noffsinger, “TP53 and Gastric Carcinoma: A Review,” Human Mutation 21, no. 3 (2003): 258–270.

[124] L. An, Y. Han, S. Jiao, and Z. Zhou, “Road of No Return—Loss of TP53 Paves a Defined Evolution Path From Gastric Preneoplasia-to-Cancer,” Cancer Biology & Medicine 20, no. 12 (2024): 885–890.

[125] A. Blanchet, A. Bourgmayer, J. E. Kurtz, G. Mellitzer, and C. Gaiddon, “Isoforms of the p53 Family and Gastric Cancer: A Menage a Trois for an Unfinished Affair,” Cancers (Basel) 13, no. 4 (2021): 916.

[126] P. A. Jones and D. Takai, “The Role of DNA Methylation in Mammalian Epigenetics,” Science 293, no. 5532 (2001): 1068–1070.

[127] M. M. Suzuki and A. Bird, “DNA Methylation Landscapes: Provocative Insights From Epigenomics,” Nature Reviews Genetics 9, no. 6 (2008): 465–476.

[128] R. J. Klose and A. P. Bird, “Genomic DNA Methylation: The Mark and Its Mediators,” Trends in Biochemical Sciences 31, no. 2 (2006): 89–97.

[129] J. Yang, X. Wei, Q. Wu, et al., “Clinical Significance of the Expression of DNA Methyltransferase Proteins in Gastric Cancer,” Molecular Medicine Reports 4, no. 6 (2011): 1139–1143.

[130] W. J. Ding, J. Y. Fang, X. Y. Chen, and Y. S. Peng, “The Expression and Clinical Significance of DNA Methyltransferase Proteins in Human Gastric Cancer,” Digestive Diseases and Sciences 53, no. 8 (2008): 2083–2089.

[131] X. Qian, M. A. von Wronski, and T. P. Brent, “Localization of Methylation Sites in the Human O6-Methylguanine-DNA Methyltransferase Promoter: Correlation With Gene Suppression,” Carcinogenesis 16, no. 6 (1995): 1385–1390.

[132] Z. X. Zhang, V. Kumar, R. T. Rivera, S. G. Pasion, J. Chisholm, and D. K. Biswas, “Suppression of Prolactin Gene Expression in GH Cells Correlates With Site-Specific DNA Methylation,” DNA 8, no. 8 (1989): 605–613.

[133] G. P. Pfeifer, “Defining Driver DNA Methylation Changes in Human Cancer,” International Journal of Molecular Sciences 19, no. 4 (2018): 1166.

[134] A. S. Wilson, B. E. Power, and P. L. Molloy, “DNA Hypomethylation and Human Diseases,” Biochimica et Biophysica Acta 1775, no. 1 (2007): 138–162.

[135] T. Sakai, J. Toguchida, N. Ohtani, D. W. Yandell, J. M. Rapaport, and T. P. Dryja, “Allele-Specific Hypermethylation of the Retinoblastoma Tumor-Suppressor Gene,” American Journal of Human Genetics 48, no. 5 (1991): 880–888.

[136] J. G. Herman, F. Latif, Y. Weng, et al., “Silencing of the VHL Tumor-Suppressor Gene by DNA Methylation in Renal Carcinoma,” PNAS 91, no. 21 (1994): 9700–9704.

[137] A. Merlo, J. G. Herman, L. Mao, et al., “5' CpG Island Methylation Is Associated With Transcriptional Silencing of the Tumour Suppressor p16/CDKN2/MTS1 in Human Cancers,” Nature Medicine 1, no. 7 (1995): 686–692.

[138] M. Esteller, “CpG Island Hypermethylation and Tumor Suppressor Genes: A Booming Present, a Brighter Future,” Oncogene 21, no. 35 (2002): 5427–5440.

[139] J. A. Rusiecki, M. Al-Nabhani, L. Tarantini, L. Chen, A. Baccarelli, and M. S. Al-Moundhri, “Global DNA Methylation and Tumor Suppressor Gene Promoter Methylation and Gastric Cancer Risk in an Omani Arab Population,” Epigenomics 3, no. 4 (2011): 417–429.

[140] M. G. Borrello, M. A. Pierotti, I. Bongarzone, R. Donghi, P. Mondellini, and G. Della Porta, “DNA Methylation Affecting the Transforming Activity of the Human Ha-ras Oncogene,” Cancer Research 47, no. 1 (1987): 75–79.

[141] I. Sardi, M. Dal Canto, R. Bartoletti, and E. Montali, “Abnormal c-myc Oncogene DNA Methylation in Human Bladder Cancer: Possible Role in Tumor Progression,” European Urology 31, no. 2 (1997): 224–230.

[142] C. F. Meng, X. J. Zhu, G. Peng, and D. Q. Dai, “Promoter Histone H3 Lysine 9 Di-Methylation Is Associated With DNA Methylation and Aberrant Expression of p16 in Gastric Cancer Cells,” Oncology Reports 22, no. 5 (2009): 1221–1227.

[143] H. L. Xiong, X. Q. Liu, A. H. Sun, Y. He, J. Li, and Y. Xia, “Aberrant DNA Methylation of P16, MGMT, hMLH1 and hMSH2 Genes in Combination With the MTHFR C677T Genetic Polymorphism in Gastric Cancer,” Asian Pacific Journal of Cancer Prevention 14, no. 5 (2013): 3139–3142.

[144] M. Ye, B. Xia, Q. Guo, F. Zhou, and X. Zhang, “Association of Diminished Expression of RASSF1A With Promoter Methylation in Primary Gastric Cancer From Patients of Central China,” BMC Cancer 7 (2007): 120.

[145] Q. Yang, Y. Shao, J. Shi, et al., “Concomitant PIK3CA Amplification and RASSF1A or PAX6 Hypermethylation Predict Worse Survival in Gastric Cancer,” Clinical Biochemistry 47, no. 1–2 (2014): 111–116.

[146] W. J. Shen, D. Q. Dai, Y. Teng, and H. B. Liu, “Regulation of Demethylation and Re-expression of RASSF1A Gene in Gastric Cancer Cell Lines by Combined Treatment of 5-Aza-CdR and NaB,” World Journal of Gastroenterology 14, no. 4 (2008): 595–600.

[147] T. Ando, Y. Goto, O. Maeda, O. Watanabe, K. Ishiguro, and H. Goto, “Causal Role of Helicobacter pylori Infection in Gastric Cancer,” World Journal of Gastroenterology 12, no. 2 (2006): 181–186.

[148] F. Perri, R. Cotugno, A. Piepoli, et al., “Aberrant DNA Methylation in Non-Neoplastic Gastric Mucosa of H. pylori Infected Patients and Effect of Eradication,” American Journal of Gastroenterology 102, no. 7 (2007): 1361–1371.

[149] Y. Zhang, D. Chen, L. Zhang, et al., “Helicobacter pylori Associated Aberrant Methylation Genes in Blood Leukocyte and Gastric Mucosa,” Journal of Cancer 12, no. 24 (2021): 7326–7333.

[150] M. Maeda, H. Moro, and T. Ushijima, “Mechanisms for the Induction of Gastric Cancer by Helicobacter pylori Infection: Aberrant DNA Methylation Pathway,” Gastric Cancer 20, no. suppl 1 (2017): 8–15.

[151] C. M. Shin, N. Kim, Y. Jung, et al., “Genome-Wide DNA Methylation Profiles in Noncancerous Gastric Mucosae With Regard to Helicobacter pylori Infection and the Presence of Gastric Cancer,” Helicobacter 16, no. 3 (2011): 179–188.

[152] K. Matsusaka, S. Funata, M. Fukayama, and A. Kaneda, “DNA Methylation in Gastric Cancer, Related to Helicobacter pylori and Epstein-Barr Virus,” World Journal of Gastroenterology 20, no. 14 (2014): 3916–3926.

[153] K. Matsusaka, S. Funata, M. Fukuyo, et al., “Epstein-Barr Virus Infection Induces Genome-Wide De Novo DNA Methylation in Non-Neoplastic Gastric Epithelial Cells,” Journal of Pathology 242, no. 4 (2017): 391–399.

[154] M. Saito, J. Nishikawa, T. Okada, et al., “Role of DNA Methylation in the Development of Epstein-Barr Virus-Associated Gastric Carcinoma,” Journal of Medical Virology 85, no. 1 (2013): 121–127.

[155] K. Luger, A. W. Mader, R. K. Richmond, D. F. Sargent, and T. J. Richmond, “Crystal Structure of the Nucleosome Core Particle at 2.8 A Resolution,” Nature 389, no. 6648 (1997): 251–260.

[156] J. Fuchs, D. Demidov, A. Houben, and I. Schubert, “Chromosomal Histone Modification Patterns–From Conservation to Diversity,” Trends in Plant Science 11, no. 4 (2006): 199–208.

[157] C. Sawan and Z. Herceg, “Histone Modifications and Cancer,” Advances in Genetics 70 (2010): 57–85.

[158] Y. Zhang and D. Reinberg, “Transcription Regulation by Histone Methylation: Interplay Between Different Covalent Modifications of the Core Histone Tails,” Genes & Development 15, no. 18 (2001): 2343–2360.

[159] A. Shilatifard, “Chromatin Modifications by Methylation and Ubiquitination: Implications in the Regulation of Gene Expression,” Annual Review of Biochemistry 75 (2006): 243–269.

[160] D. J. Burgess, “Cancer Genomics: Histone Modification at the Gene Level,” Nature Reviews Genetics 13, no. 3 (2012): 148–149.

[161] C. Martin and Y. Zhang, “The Diverse Functions of Histone Lysine Methylation,” Nature Reviews Molecular Cell Biology 6, no. 11 (2005): 838–849.

[162] A. Di Lorenzo and M. T. Bedford, “Histone Arginine Methylation,” FEBS Letters 585, no. 13 (2011): 2024–2031.

[163] H. Cui, Y. Hu, D. Guo, et al., “DNA Methyltransferase 3A Isoform b Contributes to Repressing E-Cadherin Through Cooperation of DNA Methylation and H3K27/H3K9 Methylation in EMT-Related Metastasis of Gastric Cancer,” Oncogene 37, no. 32 (2018): 4358–4371.

[164] J. Wu, H. Chai, X. Xu, J. Yu, and Y. Gu, “Histone Methyltransferase SETD1A Interacts With HIF1alpha to Enhance Glycolysis and Promote Cancer Progression in Gastric Cancer,” Molecular Oncology 14, no. 6 (2020): 1397–1409.

[165] M. Liu, B. Yao, T. Gui, et al., “PRMT5-Dependent Transcriptional Repression of c-Myc Target Genes Promotes Gastric Cancer Progression,” Theranostics 10, no. 10 (2020): 4437–4452.

[166] M. Grunstein, “Histone Acetylation in Chromatin Structure and Transcription,” Nature 389, no. 6649 (1997): 349–352.

[167] H. J. Fei, L. D. Zu, J. Wu, et al., “PCAF Acts as a Gastric Cancer Suppressor Through a Novel PCAF-p16-CDK4 Axis,” American Journal of Cancer Research 6, no. 12 (2016): 2772–2786.

[168] K. Sakuraba, K. Yokomizo, A. Shirahata, et al., “TIP60 as a Potential Marker for the Malignancy of Gastric Cancer,” Anticancer Research 31, no. 1 (2011): 77–79.

[169] K. Mutze, R. Langer, K. Becker, et al., “Histone Deacetylase (HDAC) 1 and 2 Expression and Chemotherapy in Gastric Cancer,” Annals of Surgical Oncology 17, no. 12 (2010): 3336–3343.

[170] J. K. Kim, J. H. Noh, J. W. Eun, et al., “Targeted Inactivation of HDAC2 Restores p16INK4a Activity and Exerts Antitumor Effects on Human Gastric Cancer,” Molecular Cancer Research 11, no. 1 (2013): 62–73.

[171] D. Zhang, Z. Tang, H. Huang, et al., “Metabolic Regulation of Gene Expression by Histone Lactylation,” Nature 574, no. 7779 (2019): 575–580.

[172] E. L. Mills, D. G. Ryan, H. A. Prag, et al., “Itaconate Is an Anti-Inflammatory Metabolite That Activates Nrf2 via Alkylation of KEAP1,” Nature 556, no. 7699 (2018): 113–117.

[173] Y. Yao, G. Kim, S. Shafer, et al., “Mucus Sialylation Determines Intestinal Host-Commensal Homeostasis,” Cell 185, no. 7 (2022): 1172–1188. e28.

[174] X. D. He, W. Gong, J. N. Zhang, et al., “Sensing and Transmitting Intracellular Amino Acid Signals Through Reversible Lysine Aminoacylations,” Cell Metabolism 27, no. 1 (2018): 151–166. e6.

[175] N. A. Muma and Z. Mi, “Serotonylation and Transamidation of Other Monoamines,” ACS Chemical Neuroscience 6, no. 7 (2015): 961–969.

[176] A. Al-Kachak and I. Maze, “Post-translational Modifications of Histone Proteins by Monoamine Neurotransmitters,” Current Opinion in Chemical Biology 74 (2023): 102302.

[177] R. Zhuang and C. Khosla, “Substrates, Inhibitors, and Probes of Mammalian Transglutaminase 2,” Analytical Biochemistry 591 (2020): 113560.

[178] L. A. Farrelly, R. E. Thompson, S. Zhao, et al., “Histone Serotonylation Is a Permissive Modification That Enhances TFIID Binding to H3K4me3,” Nature 567, no. 7749 (2019): 535–539.

[179] X. Wang, S. Q. Fu, X. Yuan, et al., “A GAPDH Serotonylation System Couples CD8(+) T Cell Glycolytic Metabolism to Antitumor Immunity,” Molecular Cell 84, no. 4 (2024): 760–775. e7.

[180] K. Liu, Y. Zhang, G. Du, et al., “5-HT Orchestrates Histone Serotonylation and Citrullination to Drive Neutrophil Extracellular Traps and Liver Metastasis,” Journal of Clinical Investigation 135, no. 8 (2025): e183544.

[181] A. E. Lepack, C. T. Werner, A. F. Stewart, et al., “Dopaminylation of Histone H3 in Ventral Tegmental Area Regulates Cocaine Seeking,” Science 368, no. 6487 (2020): 197–201.

[182] C. Mo, H. Li, M. Yan, et al., “Dopaminylation of Endothelial TPI1 Suppresses Ferroptotic Angiocrine Signals to Promote Lung Regeneration Over Fibrosis,” Cell Metabolism 36, no. 8 (2024): 1839–1857. e12.

[183] Q. Zheng, B. H. Weekley, D. A. Vinson, et al., “Bidirectional Histone Monoaminylation Dynamics Regulate Neural Rhythmicity,” Nature 637, no. 8047 (2025): 974–982.

[184] Q. Yao, Y. Chen, and X. Zhou, “The Roles of microRNAs in Epigenetic Regulation,” Current Opinion in Chemical Biology 51 (2019): 11–17.

[185] H. Wang, X. Zhang, Y. Liu, et al., “Downregulated miR-31 Level Associates With Poor Prognosis of Gastric Cancer and Its Restoration Suppresses Tumor Cell Malignant Phenotypes by Inhibiting E2F2,” Oncotarget 7, no. 24 (2016): 36577–36589.

[186] Z. Zhang and D. Q. Dai, “MicroRNA-596 Acts as a Tumor Suppressor in Gastric Cancer and Is Upregulated by Promotor Demethylation,” World Journal of Gastroenterology 25, no. 10 (2019): 1224–1237.

[187] J. F. Zeng, X. Q. Ma, L. P. Wang, and W. Wang, “MicroRNA-145 Exerts Tumor-Suppressive and Chemo-Resistance Lowering Effects by Targeting CD44 in Gastric Cancer,” World Journal of Gastroenterology 23, no. 13 (2017): 2337–2345.

[188] Z. Jiang, J. Guo, B. Xiao, et al., “Increased Expression of miR-421 in Human Gastric Carcinoma and Its Clinical Association,” Journal of Gastroenterology 45, no. 1 (2010): 17–23.

[189] B. Xiao, J. Guo, Y. Miao, et al., “Detection of miR-106a in Gastric Carcinoma and Its Clinical Significance,” Clinica Chimica Acta 400, no. 1–2 (2009): 97–102.

[190] P. S. Mitchell, R. K. Parkin, E. M. Kroh, et al., “Circulating microRNAs as Stable Blood-Based Markers for Cancer Detection,” PNAS 105, no. 30 (2008): 10513–10518.

[191] R. Liu, C. Zhang, Z. Hu, et al., “A Five-microRNA Signature Identified From Genome-Wide Serum microRNA Expression Profiling Serves as a Fingerprint for Gastric Cancer Diagnosis,” European Journal of Cancer 47, no. 5 (2011): 784–791.

[192] L. Statello, C. J. Guo, L. L. Chen, and M. Huarte, “Gene Regulation by Long Non-Coding RNAs and Its Biological Functions,” Nature Reviews Molecular Cell Biology 22, no. 2 (2021): 96–118.

[193] D. W. Thomson and M. E. Dinger, “Endogenous microRNA Sponges: Evidence and Controversy,” Nature Reviews Genetics 17, no. 5 (2016): 272–283.

[194] D. Wu, H. Li, J. Wang, et al., “LncRNA NEAT1 Promotes Gastric Cancer Progression via miR-1294/AKT1 Axis,” Open Medicine (Warsaw) 15, no. 1 (2020): 1028–1038.

[195] W. Peng, S. Si, Q. Zhang, et al., “Long Non-Coding RNA MEG3 Functions as a Competing Endogenous RNA to Regulate Gastric Cancer Progression,” Journal of Experimental & Clinical Cancer Research 34 (2015): 79.

[196] J. B. Furness, “The Enteric Nervous System and Neurogastroenterology,” Nature Reviews Gastroenterology & Hepatology 9, no. 5 (2012): 286–294.

[197] M. Rao and M. D. Gershon, “The Bowel and Beyond: The Enteric Nervous System in Neurological Disorders,” Nature Reviews Gastroenterology & Hepatology 13, no. 9 (2016): 517–528.

[198] L. Wang, J. Xu, Y. Xia, et al., “Muscarinic Acetylcholine Receptor 3 Mediates Vagus Nerve-Induced Gastric Cancer,” Oncogenesis 7, no. 11 (2018): 88.

[199] C. M. Zhao, Y. Hayakawa, Y. Kodama, et al., “Denervation Suppresses Gastric Tumorigenesis,” Science Translational Medicine 6, no. 250 (2014): 250ra115.

[200] Y. Hayakawa, K. Sakitani, M. Konishi, et al., “Nerve Growth Factor Promotes Gastric Tumorigenesis Through Aberrant Cholinergic Signaling,” Cancer Cell 31, no. 1 (2017): 21–34.

[201] L. Wang, X. Zhi, Q. Zhang, et al., “Muscarinic Receptor M3 Mediates Cell Proliferation Induced by Acetylcholine and Contributes to Apoptosis in Gastric Cancer,” Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine 37, no. 2 (2016): 2105–2117.

[202] X. Zhang, Y. Zhang, Z. He, et al., “Chronic Stress Promotes Gastric Cancer Progression and Metastasis: An Essential Role for ADRB2,” Cell Death & Disease 10, no. 11 (2019): 788.

[203] C. Pan, J. Wu, S. Zheng, et al., “Depression Accelerates Gastric Cancer Invasion and Metastasis by Inducing a Neuroendocrine Phenotype via the Catecholamine/β(2) -AR/MACC1 Axis,” Cancer Commun (London) 41, no. 10 (2021): 1049–1070.

[204] N. Satoh-Takayama, T. Kato, Y. Motomura, et al., “Bacteria-Induced Group 2 Innate Lymphoid Cells in the Stomach Provide Immune Protection Through Induction of IgA,” Immunity 52, no. 4 (2020): 635–649.e4.

[205] A. R. Meyer, A. C. Engevik, T. Madorsky, et al., “Group 2 Innate Lymphoid Cells Coordinate Damage Response in the Stomach,” Gastroenterology 159, no. 6 (2020): 2077–2091.e8.

[206] M. Liu, Q. Liu, Q. Zou, et al., “The Composition and Roles of Gastric Stem Cells in Epithelial Homeostasis, Regeneration, and Tumorigenesis,” Cellular Oncology (Dordrecht) 46, no. 4 (2023): 867–883.

[207] Z. F. Miao, J. X. Sun, X. Z. Huang, et al., “Metaplastic Regeneration in the Mouse Stomach Requires a Reactive Oxygen Species Pathway,” Developmental Cell 59, no. 9 (2024): 1175–1191 e7.

[208] J. T. Busada, K. N. Peterson, S. Khadka, et al., “Glucocorticoids and Androgens Protect from Gastric Metaplasia by Suppressing Group 2 Innate Lymphoid Cell Activation,” Gastroenterology 161, no. 2 (2021): 637–652.e4.

[209] S. Tu, G. Bhagat, G. Cui, et al., “Overexpression of Interleukin-1beta Induces Gastric Inflammation and Cancer and Mobilizes Myeloid-derived Suppressor Cells in Mice,” Cancer Cell 14, no. 5 (2008): 408–419.

[210] L. A. O'Reilly, T. L. Putoczki, L. A. Mielke, et al., “Loss of NF-κB1 Causes Gastric Cancer With Aberrant Inflammation and Expression of Immune Checkpoint Regulators in a STAT-1-Dependent Manner,” Immunity 48, no. 3 (2018): 570-583 e8.

[211] P. Wang, Y. Wang, S. A. Langley, et al., “Diverse Tumour Susceptibility in Collaborative Cross Mice: Identification of a New Mouse Model for Human Gastric Tumourigenesis,” Gut 68, no. 11 (2019): 1942–1952.

[212] W. Kim, T. H. Chu, H. Nienhüser, et al., “PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice,” Gastroenterology 160, no. 3 (2021): 781–796.

[213] P. Nie, W. Zhang, Y. Meng, et al., “A YAP/TAZ-CD54 Axis Is Required for CXCR2-CD44- Tumor-Specific Neutrophils to Suppress Gastric Cancer,” Protein Cell 14, no. 7 (2023): 513–531.

[214] T. T. Wang, Y. L. Zhao, L. S. Peng, et al., “Tumour-Activated Neutrophils in Gastric Cancer Foster Immune Suppression and Disease Progression Through GM-CSF-PD-L1 Pathway,” Gut 66, no. 11 (2017): 1900–1911.

[215] X. Zhang, H. Shi, X. Yuan, P. Jiang, H. Qian, and W. Xu, “Tumor-Derived Exosomes Induce N2 Polarization of Neutrophils to Promote Gastric Cancer Cell Migration,” Molecular Cancer 17, no. 1 (2018): 146.

[216] T. A. Wynn, A. Chawla, and J. W. Pollard, “Macrophage Biology in Development, Homeostasis and Disease,” Nature 496, no. 7446 (2013): 445–455.

[217] D. G. DeNardo and B. Ruffell, “Macrophages as Regulators of Tumour Immunity and Immunotherapy,” Nature Reviews Immunology 19, no. 6 (2019): 369–382.

[218] A. Mantovani, F. Marchesi, A. Malesci, L. Laghi, and P. Allavena, “Tumour-Associated Macrophages as Treatment Targets in Oncology,” Nature Reviews Clinical Oncology 14, no. 7 (2017): 399–416.

[219] L. Miao, J. Qi, Q. Zhao, et al., “Targeting the STING Pathway in Tumor-Associated Macrophages Regulates Innate Immune Sensing of Gastric Cancer Cells,” Theranostics 10, no. 2 (2020): 498–515.

[220] G. Zhu, J. Song, W. Chen, et al., “Expression and Role of Dickkopf-1 (Dkk1) in Tumors: From the Cells to the Patients,” Cancer Management and Research 13 (2021): 659–675.

[221] X. Yang, Y. Qi, and S. Wang, “DKN-01 Suppresses Gastric Cancer Progression Through Activating cGAS-STING Pathway to Block Macrophage M2 Polarization,” Applied Biochemistry and Biotechnology 197, no. 2 (2025): 1025–1038.

[222] R. Arend, J. Dholakia, C. Castro, et al., “DKK1 is a Predictive Biomarker for Response to DKN-01: Results of a Phase 2 Basket Study in Women With Recurrent Endometrial Carcinoma,” Gynecologic Oncology 172 (2023): 82–91.

[223] S. Jiao, C. Li, F. Guo, et al., “SUN1/2 Controls Macrophage Polarization via Modulating Nuclear Size and Stiffness,” Nature Communications 14, no. 1 (2023): 6416.

[224] R. Jin, L. Neufeld, and T. L. McGaha, “Linking Macrophage Metabolism to Function in the Tumor Microenvironment,” Nature Cancer 6, no. 2 (2025): 239–252.

[225] C. Zhao, J. Gong, Y. Bai, et al., “A Self-amplifying USP14-TAZ Loop Drives the Progression and Liver Metastasis of Pancreatic Ductal Adenocarcinoma,” Cell Death and Differentiation 30, no. 1 (2023): 1–15.

[226] F. Xu, Y. Ma, W. Huang, et al., “Typically Inhibiting USP14 Promotes Autophagy in M1-Like Macrophages and Alleviates CLP-Induced Sepsis,” Cell Death & Disease 11, no. 8 (2020): 666.

[227] F. He, Y. Chen, D. He, and S. He, “USP14-Mediated Deubiquitination of SIRT1 in Macrophage Promotes Fatty Acid Oxidation Amplification and M2 Phenotype Polarization,” Biochemical and Biophysical Research Communications 646 (2023): 19–29.

[228] Q. Luo, N. Zheng, L. Jiang, et al., “Lipid Accumulation in Macrophages Confers Protumorigenic Polarization and Immunity in Gastric Cancer,” Cancer Science 111, no. 11 (2020): 4000–4011.

[229] Z. Ni, D. Xing, T. Zhang, et al., “Tumor-Infiltrating B Cell Is Associated With the Control of Progression of Gastric Cancer,” Immunologic Research 69, no. 1 (2021): 43–52.

[230] S. M. Downs-Canner, J. Meier, B. G. Vincent, and J. S. Serody, “B Cell Function in the Tumor Microenvironment,” Annual Review of Immunology 40 (2022): 169–193.

[231] G. V. Sharonov, E. O. Serebrovskaya, D. V. Yuzhakova, O. V. Britanova, and D. M. Chudakov, “B Cells, Plasma Cells and Antibody Repertoires in the Tumour Microenvironment,” Nature Reviews Immunology 20, no. 5 (2020): 294–307.

[232] V. Kumar, K. Ramnarayanan, R. Sundar, et al., “Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric Cancer,” Cancer Discovery 12, no. 3 (2022): 670–691.

[233] H. Katoh, D. Komura, H. Konishi, et al., “Immunogenetic Profiling for Gastric Cancers Identifies Sulfated Glycosaminoglycans as Major and Functional B Cell Antigens in Human Malignancies,” Cell Reports 20, no. 5 (2017): 1073–1087.

[234] C. Sautès-Fridman, F. Petitprez, J. Calderaro, and W. H. Fridman, “Tertiary Lymphoid Structures in the Era of Cancer Immunotherapy,” Nature Reviews Cancer 19, no. 6 (2019): 307–325.

[235] T. N. Schumacher and D. S. Thommen, “Tertiary Lymphoid Structures in Cancer,” Science 375, no. 6576 (2022): eabf9419.

[236] B. A. Helmink, S. M. Reddy, J. Gao, et al., “B Cells and Tertiary Lymphoid Structures Promote Immunotherapy Response,” Nature 577, no. 7791 (2020): 549–555.

[237] R. Cabrita, M. Lauss, A. Sanna, et al., “Tertiary Lymphoid Structures Improve Immunotherapy and Survival in Melanoma,” Nature 577, no. 7791 (2020): 561–565.

[238] F. Petitprez, A. de Reyniès, E. Z. Keung, et al., “B Cells Are Associated With Survival and Immunotherapy Response in Sarcoma,” Nature 577, no. 7791 (2020): 556–560.

[239] C. Sakimura, H. Tanaka, T. Okuno, et al., “B Cells in Tertiary Lymphoid Structures Are Associated With Favorable Prognosis in Gastric Cancer,” Journal of Surgical Research 215 (2017): 74–82.

[240] L. Jia, T. Wang, Y. Zhao, et al., “Single-Cell Profiling of Infiltrating B Cells and Tertiary Lymphoid Structures in the TME of Gastric Adenocarcinomas,” Oncoimmunology 10, no. 1 (2021): 1969767.

[241] B. Zhang, A. Vogelzang, M. Miyajima, et al., “B Cell-Derived GABA Elicits IL-10(+) Macrophages to Limit Anti-Tumour Immunity,” Nature 599, no. 7885 (2021): 471–476.

[242] Y. Murakami, H. Saito, S. Shimizu, et al., “Increased Regulatory B Cells Are Involved in Immune Evasion in Patients With Gastric Cancer,” Scientific Reports 9, no. 1 (2019): 13083.

[243] R. Li, H. Liu, Y. Cao, et al., “Identification and Validation of an Immunogenic Subtype of Gastric Cancer With Abundant Intratumoural CD103(+)CD8(+) T Cells Conferring Favourable Prognosis,” British Journal of Cancer 122, no. 10 (2020): 1525–1534.

[244] J. Wang, R. Li, Y. Cao, et al., “Intratumoral CXCR5(+)CD8(+)T Associates With Favorable Clinical Outcomes and Immunogenic Contexture in Gastric Cancer,” Nature Communications 12, no. 1 (2021): 3080.

[245] E. D. Thompson, M. Zahurak, A. Murphy, et al., “Patterns of PD-L1 Expression and CD8 T Cell Infiltration in Gastric Adenocarcinomas and Associated Immune Stroma,” Gut 66, no. 5 (2017): 794–801.

[246] K. Jin, Y. Cao, Y. Gu, et al., “Poor Clinical Outcomes and Immunoevasive Contexture in CXCL13+CD8+ T Cells Enriched Gastric Cancer Patients,” Oncoimmunology 10, no. 1 (2021): 1915560.

[247] E. J. Wherry and M. Kurachi, “Molecular and Cellular Insights Into T Cell Exhaustion,” Nature Reviews Immunology 15, no. 8 (2015): 486–499.

[248] H. M. Zarour, “Reversing T-Cell Dysfunction and Exhaustion in Cancer,” Clinical Cancer Research 22, no. 8 (2016): 1856–1864.

[249] Y. Shen, Y. Teng, Y. Lv, et al., “PD-1 Does Not Mark Tumor-infiltrating CD8+ T Cell Dysfunction in Human Gastric Cancer,” Journal for ImmunoTherapy of Cancer 8, no. 2 (2020): e000422.

[250] W. He, H. Zhang, F. Han, et al., “CD155T/TIGIT Signaling Regulates CD8(+) T-Cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer,” Cancer Research 77, no. 22 (2017): 6375–6388.

[251] Y. Zhuang, L. S. Peng, Y. L. Zhao, et al., “CD8(+) T Cells That Produce Interleukin-17 Regulate Myeloid-Derived Suppressor Cells and Are Associated With Survival Time of Patients With Gastric Cancer,” Gastroenterology 143, no. 4 (2012): 951-962 e8.

[252] M. C. Poffenberger, A. Metcalfe-Roach, E. Aguilar, et al., “LKB1 Deficiency in T Cells Promotes the Development of Gastrointestinal Polyposis,” Science 361, no. 6400 (2018): 406–411.

[253] T. L. Nguyen, S. S. Khurana, C. J. Bellone, et al., “Autoimmune Gastritis Mediated by CD4+ T Cells Promotes the Development of Gastric Cancer,” Cancer Research 73, no. 7 (2013): 2117–2126.

[254] W. Zhang, S. Wang, H. Zhang, et al., “Modeling Human Gastric Cancers in Immunocompetent Mice,” Cancer Biology & Medicine 21, no. 7 (2024): 553–570.

[255] L. Ji, W. Qian, L. Gui, et al., “Blockade of β-Catenin-Induced CCL28 Suppresses Gastric Cancer Progression via Inhibition of Treg Cell Infiltration,” Cancer Research 80, no. 10 (2020): 2004–2016.

[256] F. Y. Mao, H. Kong, Y. L. Zhao, et al., “Increased Tumor-Infiltrating CD45RA(-)CCR7(-) Regulatory T-Cell Subset With Immunosuppressive Properties Foster Gastric Cancer Progress,” Cell Death & Disease 8, no. 8 (2017): e3002.

[257] S. Kumagai, Y. Togashi, C. Sakai, et al., “An Oncogenic Alteration Creates a Microenvironment That Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells,” Immunity 53, no. 1 (2020): 187-203 e8.

[258] A. Tanaka and S. Sakaguchi, “Targeting Treg Cells in Cancer Immunotherapy,” European Journal of Immunology 49, no. 8 (2019): 1140–1146.

[259] A. Kuratani, M. Okamoto, K. Kishida, et al., “Platelet Factor 4-Induced T(H)1-T(reg) Polarization Suppresses Antitumor Immunity,” Science 386, no. 6724 (2024): eadn8608.

[260] M. Okamoto, M. Sasai, A. Kuratani, et al., “A Genetic Method Specifically Delineates Th1-type Treg Cells and Their Roles in Tumor Immunity,” Cell Reports 42, no. 7 (2023): 112813.

[261] P. Nie, Z. Cao, R. Yu, et al., “Targeting p97-Npl4 Interaction Inhibits Tumor T(reg) Cell Development to Enhance Tumor Immunity,” Nature Immunology 25, no. 9 (2024): 1623–1636.

[262] S. Rogers, C. Zhang, V. Anagnostidis, et al., “Cancer-Associated Fibroblasts Influence Wnt/PCP Signaling in Gastric Cancer Cells by Cytoneme-Based Dissemination of ROR2,” PNAS 120, no. 39 (2023): e2217612120.

[263] L. Wang, I. Steele, J. D. Kumar, et al., “Distinct miRNA Profiles in Normal and Gastric Cancer Myofibroblasts and Significance in Wnt Signaling,” American Journal of Physiology Gastrointestinal and Liver Physiology 310, no. 9 (2016): G696–G704.

[264] P. Li, H. Zhang, T. Chen, Y. Zhou, J. Yang, and J. Zhou, “Cancer-Associated Fibroblasts Promote Proliferation, Angiogenesis, Metastasis and Immunosuppression in Gastric Cancer,” Matrix Biology 132 (2024): 59–71.

[265] H. Sun, X. Wang, X. Wang, M. Xu, and W. Sheng, “The Role of Cancer-Associated Fibroblasts in Tumorigenesis of Gastric Cancer,” Cell Death & Disease 13, no. 10 (2022): 874.

[266] Y. Jiang, Y. Wang, G. Chen, et al., “Nicotinamide Metabolism Face-Off Between Macrophages and Fibroblasts Manipulates the Microenvironment in Gastric Cancer,” Cell Metabolism 36, no. 8 (2024): 1806–1822 e11.

[267] T. Zhang, X. Li, Y. He, et al., “Cancer-Associated Fibroblasts-Derived HAPLN1 Promotes Tumour Invasion Through Extracellular Matrix Remodeling in Gastric Cancer,” Gastric Cancer 25, no. 2 (2022): 346–359.

[268] D. Li and Y. Li, “The Interaction Between Ferroptosis and Lipid Metabolism in Cancer,” Signal Transduction and Targeted Therapy 5, no. 1 (2020): 108.

[269] L. Yao, J. Hou, X. Wu, et al., “Cancer-Associated Fibroblasts Impair the Cytotoxic Function of NK Cells in Gastric Cancer by Inducing Ferroptosis via Iron Regulation,” Redox Biology 67 (2023): 102923.

[270] G. Duru, M. van Egmond, and N. Heemskerk, “A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy,” Frontiers in Immunology 11 (2020): 584723.

[271] Z. Wu, B. Uhl, O. Gires, and C. A. Reichel, “A Transcriptomic Pan-Cancer Signature for Survival Prognostication and Prediction of Immunotherapy Response Based on Endothelial Senescence,” Journal of Biomedical Science 30, no. 1 (2023): 21.

[272] K. Sun, R. Xu, F. Ma, et al., “scRNA-seq of Gastric Tumor Shows Complex Intercellular Interaction With an Alternative T Cell Exhaustion Trajectory,” Nature Communications 13, no. 1 (2022): 4943.

[273] M. Y. Meng, L. Li, W. J. Wang, et al., “Assessment of Tumor Promoting Effects of Amniotic and Umbilical Cord Mesenchymal Stem Cells In Vitro and In Vivo,” Journal of Cancer Research and Clinical Oncology 145, no. 5 (2019): 1133–1146.

[274] F. Huang, Y. Yao, J. Wu, et al., “Curcumin Inhibits Gastric Cancer-Derived Mesenchymal Stem Cells Mediated Angiogenesis by Regulating NF-KappaB/VEGF Signaling,” American Journal of Translational Research 9, no. 12 (2017): 5538–5547.

[275] L. Cui, T. Liu, C. Huang, et al., “Gastric Cancer Mesenchymal Stem Cells Trigger Endothelial Cell Functional Changes to Promote Cancer Progression,” Stem Cell Reviews and Reports 20, no. 5 (2024): 1285–1298.

[276] Q. Wang, Q. Liu, T. Wang, H. Yang, Z. Han, and P. Zhang, “Endothelial Cell Protein C Receptor Promotes MGC803 Gastric Cancer Cells Proliferation and Migration by Activating ERK1/2,” Medical Oncology 32, no. 5 (2015): 162.

[277] Q. Wang, Y. Tang, T. Wang, et al., “EPCR Promotes MGC803 Human Gastric Cancer Cell Tumor Angiogenesis In Vitro Through Activating ERK1/2 and AKT in a PAR1-Dependent Manner,” Oncology Letters 16, no. 2 (2018): 1565–1570.

[278] D. Delgado-Bellido, S. Serrano-Saenz, M. Fernandez-Cortes, and F. J. Oliver, “Vasculogenic Mimicry Signaling Revisited: Focus on Non-Vascular VE-Cadherin,” Molecular Cancer 16, no. 1 (2017): 65.

[279] X. Wei, Y. Chen, X. Jiang, et al., “Mechanisms of Vasculogenic Mimicry in Hypoxic Tumor Microenvironments,” Molecular Cancer 20, no. 1 (2021): 7.

[280] S. Hironaka, “Anti-Angiogenic Therapies for Gastric Cancer,” Asia-Pacific Journal of Clinical Oncology 15, no. 4 (2019): 208–217.

[281] W. Wang, T. Wang, Y. Zhang, T. Deng, H. Zhang, and Y. I. Ba, “Gastric Cancer Secreted miR-214-3p Inhibits the Anti-Angiogenesis Effect of Apatinib by Suppressing Ferroptosis in Vascular Endothelial Cells,” Oncology Research 32, no. 3 (2024): 489–502.

[282] A. M. Moreira, J. Pereira, S. Melo, et al., “The Extracellular Matrix: An Accomplice in Gastric Cancer Development and Progression,” Cells 9, no. 2 (2020): 394.

[283] H. J. Lee, Y. Kwak, Y. S. Na, et al., “Proteomic Heterogeneity of the Extracellular Matrix Identifies Histologic Subtype-Specific Fibroblast in Gastric Cancer,” Molecular & Cellular Proteomics 23, no. 10 (2024): 100843.

[284] L. J. S. Kemp, J. L. Monster, C. S. Wood, et al., “Tumour-Intrinsic Alterations and Stromal Matrix Remodelling Promote Wnt-Niche Independence During Diffuse-Type Gastric Cancer Progression,” Gut 74, no. 8 (2025): 1219–1229.

[285] C. He, Z. Zhou, Y. Yang, S. Zhu, H. Wang, and L. Teng, “FERMT2 Drives Anoikis Resistance and Peritoneal Metastasis by Enhancing Extracellular Matrix Deposition in Gastric Cancer,” Gastric Cancer 28, no. 3 (2025): 409–421.

[286] Z. Wei, J. Li, L. Zhong, et al., “DDR1 Drives Malignant Progression of Gastric Cancer by Suppressing HIF-1Alpha Ubiquitination and Degradation,” Advanced Science (Weinheim) 11, no. 35 (2024): e2308395.

[287] X. Wang, X. Shi, H. Lu, et al., “Succinylation Inhibits the Enzymatic Hydrolysis of the Extracellular Matrix Protein Fibrillin 1 and Promotes Gastric Cancer Progression,” Advanced Science (Weinheim) 9, no. 27 (2022): e2200546.

[288] A. Capuano, M. Vescovo, S. Canesi, et al., “The Extracellular Matrix Protein EMILIN-1 Impacts on the Microenvironment by Hampering Gastric Cancer Development and Progression,” Gastric Cancer 27, no. 5 (2024): 1016–1030.

[289] X. He, L. Zhong, N. Wang, et al., “Gastric Cancer Actively Remodels Mechanical Microenvironment to Promote Chemotherapy Resistance via MSCs-Mediated Mitochondrial Transfer,” Advanced Science (Weinheim) 11, no. 47 (2024): e2404994.

[290] L. Ji, J. Peng, Y. Lin, et al., “High Extracellular Matrix Stiffness Upregulates TNNT1 to Awaken Dormant Tumor Cells in Liver Metastatic Niches of Gastric Cancer,” Cellular Oncology (Dordrecht) 48, no. 3 (2025): 815–834.

[291] P. Romani, L. Valcarcel-Jimenez, C. Frezza, and S. Dupont, “Crosstalk Between Mechanotransduction and Metabolism,” Nature Reviews Molecular Cell Biology 22, no. 1 (2021): 22–38.

[292] H. N. Kim, M. J. Kim, J. P. Jacobs, and H. J. Yang, “Altered Gastric Microbiota and Inflammatory Cytokine Responses in Patients With Helicobacter pylori-Negative Gastric Cancer,” Nutrients 14, no. 23 (2022): 4981.

[293] X. Y. Yuan, Y. Zhang, X. Zhao, A. Chen, and P. Liu, “IL-1Beta, an Important Cytokine Affecting Helicobacter pylori-Mediated Gastric Carcinogenesis,” Microbial Pathogenesis 174 (2023): 105933.

[294] M. Zeyaullah, A. M. AlShahrani, and I. Ahmad, “Association of Helicobacter pylori Infection and Host Cytokine Gene Polymorphism With Gastric Cancer,” Canadian Journal of Gastroenterology & Hepatology 2021 (2021): 8810620.

[295] Z. Shaibu, I. A. Danbala, Z. Chen, and W. Zhu, “Role of Mesenchymal Stem Cells in Modulating Cytokine Networks and Immune Checkpoints in Gastric Cancer Therapy,” Biochimica et Biophysica Acta-Reviews on Cancer 1880, no. 5 (2025): 189433.

[296] F. Lospinoso Severini, G. Falco, and T. Notarangelo, “Role of Soluble Cytokine Receptors in Gastric Cancer Development and Chemoresistance,” International Journal of Molecular Sciences 26, no. 6 (2025): 2534.

[297] Y. Oya, Y. Hayakawa, and K. Koike, “Tumor Microenvironment in Gastric Cancers,” Cancer Science 111, no. 8 (2020): 2696–2707.

[298] X. K. Cao, B. Xie, Y. Shao, and J. Lin, “Cytokine-Driven Positive Feedback Loop Organizes Fibroblast Transformation and Facilitates Gastric Cancer Progression,” Clinical & Translational Oncology 24, no. 7 (2022): 1354–1364.

[299] T. Yasuda, M. Koiwa, A. Yonemura, et al., “Inflammation-Driven Senescence-Associated Secretory Phenotype in Cancer-Associated Fibroblasts Enhances Peritoneal Dissemination,” Cell Reports 34, no. 8 (2021): 108779.

[300] S. Qin, Q. Guo, Y. Liu, et al., “A Novel TGFbeta/TGILR Axis Mediates Crosstalk Between Cancer-Associated Fibroblasts and Tumor Cells to Drive Gastric Cancer Progression,” Cell Death & Disease 15, no. 5 (2024): 368.

[301] F. Yang, Z. Shaibu, Q. Liu, and W. Zhu, “Cytokine Profiles as Predictive Biomarkers for Treatment Outcomes in Advanced Gastric Cancer Patients Undergoing PD-1 Blockade Immunochemotherapy: A Meta-Analysis,” Clinical and Experimental Medicine 25, no. 1 (2025): 136.

[302] M. M. C. Marimuthu, B. S. Balamurugan, V. A. Sundaram, S. Anbalagan, and H. Chopra, “Cytokine-Based Immunotherapy for Gastric Cancer: Targeting Inflammation for Tumor Control,” Exploration of Targeted Anti-Tumor Therapy 6 (2025): 1002312.

[303] Z. Cheng, X. Cui, S. Li, et al., “Harnessing Cytokines to Optimize Chimeric Antigen Receptor-T Cell Therapy for Gastric Cancer: Current Advances and Innovative Strategies,” Biomedicine & Pharmacotherapy 178 (2024): 117229.

[304] Z. Li and H. Zhang, “Reprogramming of Glucose, Fatty Acid and Amino Acid Metabolism for Cancer Progression,” Cellular and Molecular Life Sciences 73, no. 2 (2016): 377–392.

[305] J.-W. Kim, I. Tchernyshyov, G. L. Semenza, and C. V. Dang, “HIF-1-Mediated Expression of Pyruvate Dehydrogenase Kinase: A Metabolic Switch Required for Cellular Adaptation to Hypoxia,” Cell Metabolism 3, no. 3 (2006): 177–185.

[306] S. Lin, R. Ma, X. Y. Zheng, H. Yu, and X. Liang, “Meta-Analysis of Immunohistochemical Expression of Hypoxia Inducible Factor-1α as a Prognostic Role in Gastric Cancer,” World Journal of Gastroenterology 28, no. 4 (2014): 1107–1113.

[307] H. B. Wang, C. J. Zhou, S. Z. Song, et al., “Evaluation of Nrf2 and IGF-1 Expression in Benign, Premalignant and Malignant Gastric Lesions,” Pathology, Research and Practice 207, no. 3 (2011): 169–173.

[308] M. Gryko, J. Kisluk, D. Cepowicz, et al., “Expression of Insulin-Like Growth Factor Receptor Type 1 Correlate With Lymphatic Metastases in Human Gastric Cancer,” Polish Journal of Pathology 65, no. 2 (2014): 135–140.

[309] O. Tapia, I. Riquelme, P. Leal, et al., “The PI3K/AKT/mTOR Pathway Is Activated in Gastric Cancer With Potential Prognostic and Predictive Significance,” Virchows Archiv 465, no. 1 (2014): 25–33.

[310] P. L. Pedersen, “Warburg, Me and Hexokinase 2: Multiple Discoveries of Key Molecular Events Underlying One of Cancers' most Common Phenotypes, the “Warburg Effect”, i.e., Elevated Glycolysis in the Presence of Oxygen,” Journal of Bioenergetics and Biomembranes 39, no. 3 (2007): 211–222.

[311] Q. Luo, N. S. Zheng, L. Jiang, T. T. Wang, and P. Zhang, “Lipid Accumulation in Macrophages Confers Protumorigenic Polarization and Immunity in Gastric Cancer,” Cancer Science 111 (2020): 4000–4011.

[312] R. Lin, H. Zhang, Y. Yuan, et al., “Fatty Acid Oxidation Controls CD8(+) Tissue-Resident Memory T-Cell Survival in Gastric Adenocarcinoma,” Cancer Immunology Research 8, no. 4 (2020): 479–492.

[313] M. Jiang, N. Wu, B. Xu, et al., “Fatty Acid-Induced CD36 Expression via O-GlcNAcylation Drives Gastric Cancer Metastasis,” Theranostics 9, no. 18 (2019): 5359–5373.

[314] E. Currie, A. Schulze, R. Zechner, T. C. Walther, and R. V. Farese, “Cellular Fatty Acid Metabolism and Cancer,” Cell Metabolism 18, no. 2 (2013): 153–161.

[315] S. Y. Xiao and L. Zhou, “Gastric Cancer: Metabolic and Metabolomics Perspectives (Review),” International Journal of Oncology 51 (2017): 5–17.

[316] T. Agustsson, M. Ryden, J. Hoffstedt, et al., “Mechanism of Increased Lipolysis in Cancer Cachexia,” Cancer Research 67, no. 11 (2007): 5531–5537.

[317] S. Li, T. Wu, Y. X. Lu, J. X. Wang, and F. H. Yu, “Obesity Promotes Gastric Cancer Metastasis via Diacylglycerol Acyltransferase 2-Dependent Lipid Droplets Accumulation and Redox Homeostasis,” Redox Biology 36 (2020): 101596.

[318] J. J. Zhao, C. J. Ong, S. Srivastava, et al., “Spatially Resolved Niche and Tumor Microenvironmental Alterations in Gastric Cancer Peritoneal Metastases,” Gastroenterology 167, no. 7 (2024): 1384–1398 e4.

[319] W. C. Chang, S. F. Huang, Y. M. Lee, H. C. Lai, and B. H. Cheng, “Cholesterol Import and Steroidogenesis Are Biosignatures for Gastric Cancer Patient Survival,” Oncotarget 8, no. 1 (2017): 692–704.

[320] G. Y. Pih, E. J. Gong, J. Y. Choi, M. J. Kim, and J. S. Ahn, “Associations of Serum Lipid Level With Gastric Cancer Risk, Pathology, and Prognosis,” Cancer Research and Treatment 53, no. 2 (2021): 445–456.

[321] F. Y. Jing, X. Hu, Y. F. Cao, M. H. Xu, and Y. Y. Wang, “Discriminating Gastric Cancer and Gastric Ulcer Using Human Plasma Amino Acid Metabolic Profile,” IUBMB Life 70, no. 6 (2018): 553–562.

[322] J. Jung, Y. Jung, E. J. Bang, et al., “Noninvasive Diagnosis and Evaluation of Curative Surgery for Gastric Cancer by Using NMR-Based Metabolomic Profiling,” Annals of Surgical Oncology 21, no. suppl 4 (2014): S736–S742.

[323] J. L. Chen, H. Q. Tang, J. D. Hu, J. Fan, J. Hong, and J. Z. Gu, “Metabolomics of Gastric Cancer Metastasis Detected by Gas Chromatography and Mass Spectrometry,” World Journal of Gastroenterology 16, no. 46 (2010): 5874–5880.

[324] H. Ma, J. Wu, M. Zhou, et al., “Inhibition of Glutamine Uptake Improves the Efficacy of Cetuximab on Gastric Cancer,” Integrative Cancer Therapies 20 (2021): 15347354211045349.

[325] W. Liu, A. Le, C. Hancock, et al., “Reprogramming of Proline and Glutamine Metabolism Contributes to the Proliferative and Metabolic Responses Regulated by Oncogenic Transcription Factor c-MYC,” PNAS 109, no. 23 (2012): 8983–8988.

[326] K. Nie and M. Cai, “SNAT2/SLC38A2 Confers the Stemness of Gastric Cancer Cells via Regulating Glutamine Level,” Digestive Diseases and Sciences 67, no. 7 (2021): 2948–2956.

[327] J. Ye, Q. Huang, J. Xu, et al., “Targeting of Glutamine Transporter ASCT2 and Glutamine Synthetase Suppresses Gastric Cancer Cell Growth,” Journal of Cancer Research and Clinical Oncology 144, no. 5 (2018): 821–833.

[328] L. Ding, J. Chakrabarti, S. Sheriff, et al., “Toll Like Receptor 9 Pathway Mediates Schlafen(+)-MDSC Polarization during Helicobacter-Induced Gastric Metaplasias,” Gastroenterology 163, no. 2 (2022): 411–425.e4.

[329] X. Wu, T. Li, R. Jiang, X. Yang, H. Guo, and R. Yang, “Targeting MHC-I Molecules for Cancer: Function, Mechanism, and Therapeutic Prospects,” Molecular Cancer 22, no. 1 (2023): 194.

[330] M. F. Eissmann, C. Dijkstra, A. Jarnicki, et al., “IL-33-Mediated Mast Cell Activation Promotes Gastric Cancer Through Macrophage Mobilization,” Nature Communications 10, no. 1 (2019): 2735.

[331] J. Wang, J. Ge, Y. Wang, et al., “EBV miRNAs BART11 and BART17-3p Promote Immune Escape Through the Enhancer-Mediated Transcription of PD-L1,” Nature Communications 13, no. 1 (2022): 866.

[332] X. Duan, H. Chen, X. Zhou, et al., “EBV Infection in Epithelial Malignancies Induces Resistance to Antitumor Natural Killer Cells via F3-Mediated Platelet Aggregation,” Cancer Research 82, no. 6 (2022): 1070–1083.

[333] J. Hwang and J. Carr, “Lymphadenectomy for Gastric Cancer,” Surgical Clinics of North America 105, no. 1 (2025): 47–54.

[334] G. Zhang, Z. Gao, X. Guo, et al., “CAP2 promotes Gastric Cancer Metastasis by Mediating the Interaction Between Tumor Cells and Tumor-Associated Macrophages,” Journal of Clinical Investigation 133, no. 21 (2023): e166224.

[335] R. Sitarz, M. Skierucha, J. Mielko, G. J. A. Offerhaus, R. Maciejewski, and W. P. Polkowski, “Gastric Cancer: Epidemiology, Prevention, Classification, and Treatment,” Cancer Management and Research 10 (2018): 239–248.

[336] E. Van Cutsem, X. Sagaert, B. Topal, K. Haustermans, and H. Prenen, “Gastric Cancer,” Lancet 388, no. 10060 (2016): 2654–2664.

[337] C. Lin, H. He, H. Liu, et al., “Tumour-Associated Macrophages-Derived CXCL8 Determines Immune Evasion Through Autonomous PD-L1 Expression in Gastric Cancer,” Gut 68, no. 10 (2019): 1764–1773.

[338] H. Jiang, D. Yu, P. Yang, et al., “Revealing the Transcriptional Heterogeneity of Organ-Specific Metastasis in Human Gastric Cancer Using Single-Cell RNA Sequencing,” Clinical and Translational Medicine 12, no. 2 (2022): e730.

[339] J. Y. Deng and H. Liang, “Clinical Significance of Lymph Node Metastasis in Gastric Cancer,” World Journal of Gastroenterology 20, no. 14 (2014): 3967–3975.

[340] J. Xu, C. Zhang, Y. He, et al., “Lymphatic Endothelial Cell-Secreted CXCL1 Stimulates Lymphangiogenesis and Metastasis of Gastric Cancer,” International Journal of Cancer 130, no. 4 (2012): 787–797.

[341] M. Wang, W. Cai, A. J. Yang, et al., “Gastric Cancer Cell-Derived Extracellular Vesicles Disrupt Endothelial Integrity and Promote Metastasis,” Cancer Letters 545 (2022): 215827.

[342] Y. X. Gwee, D. K. A. Chia, J. So, et al., “Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis,” Journal of Clinical Oncology 40, no. 24 (2022): 2830.

[343] X. Fu, Q. Wang, H. Du, and H. Hao, “CXCL8 and the Peritoneal Metastasis of Ovarian and Gastric Cancer,” Frontiers in Immunology 14 (2023): 1159061.

[344] H. Saito, S. Fushida, S. Harada, et al., “Importance of Human Peritoneal Mesothelial Cells in the Progression, Fibrosis, and Control of Gastric Cancer: Inhibition of Growth and Fibrosis by Tranilast,” Gastric Cancer 21, no. 1 (2018): 55–67.

[345] K. A. Lewis, L. P. Diggs, and B. D. Badgwell, “Educational Review: Updates on Therapeutic Strategies for Gastric Cancer With Peritoneal Metastasis,” Annals of Surgical Oncology 32, no. 5 (2025): 3672–3687.

[346] W. Li, J. M. Ng, C. C. Wong, E. K. W. Ng, and J. Yu, “Molecular Alterations of Cancer Cell and Tumour Microenvironment in Metastatic Gastric Cancer,” Oncogene 37, no. 36 (2018): 4903–4920.

[347] T. Aoki, J. Kinoshita, S. Munesue, et al., “Hypoxia-Induced CD36 Expression in Gastric Cancer Cells Promotes Peritoneal Metastasis via Fatty Acid Uptake,” Annals of Surgical Oncology 30, no. 5 (2023): 3125–3136.

[348] X. Z. Huang, M. J. Pang, J. Y. Li, et al., “Single-Cell Sequencing of Ascites Fluid Illustrates Heterogeneity and Therapy-Induced Evolution During Gastric Cancer Peritoneal Metastasis,” Nature Communications 14, no. 1 (2023): 822.

[349] M. Deng, Y. Zhang, B. Liu, et al., “beta-Elemene Inhibits Peritoneal Metastasis of Gastric Cancer Cells by Modulating FAK/Claudin-1 Signaling,” Phytotherapy Research 33, no. 9 (2019): 2448–2456.

[350] L. Liu, Y. Ye, and X. Zhu, “MMP-9 Secreted by Tumor Associated Macrophages Promoted Gastric Cancer Metastasis Through a PI3K/AKT/Snail Pathway,” Biomedicine & Pharmacotherapy 117 (2019): 109096.

[351] W. Q. Qi, Q. Zhang, and J. B. Wang, “CXCL8 Is a Potential Biomarker for Predicting Disease Progression in Gastric Carcinoma,” Translational Cancer Research 9, no. 2 (2020): 1053–1062.

[352] M. Riihimaki, A. Hemminki, K. Sundquist, J. Sundquist, and K. Hemminki, “Metastatic Spread in Patients With Gastric Cancer,” Oncotarget 7, no. 32 (2016): 52307–52316.

[353] S. Teshima, K. Kakizaki, T. Saito, T. Yokota, and H. Yamauchi, “Clinicopathological Study for Gastric Cancer With Liver Metastasis,” Upsala Journal of Medical Sciences 107, no. 2 (2002): 61–70.

[354] J. R. Yu, Y. J. Wu, Q. Qin, et al., “Expression of Cyclooxygenase-2 in Gastric Cancer and Its Relation to Liver Metastasis and Long-Term Prognosis,” World Journal of Gastroenterology 11, no. 31 (2005): 4908–4911.

[355] A. Tanio, H. Saito, M. Amisaki, et al., “AMIGO2 as a Novel Indicator of Liver Metastasis in Patients With Colorectal Cancer,” Oncology Letters 21, no. 4 (2021): 278.

[356] R. Izutsu, M. Osaki, J. P. Jehung, H. K. Seong, and F. Okada, “Liver Metastasis Formation Is Defined by AMIGO2 Expression via Adhesion to Hepatic Endothelial Cells in Human Gastric and Colorectal Cancer Cells,” Pathology, Research and Practice 237 (2022): 154015.

[357] L. Xie, S. Qiu, C. Lu, et al., “Gastric Cancer-derived LBP Promotes Liver Metastasis by Driving Intrahepatic Fibrotic Pre-Metastatic Niche Formation,” Journal of Experimental & Clinical Cancer Research 42, no. 1 (2023): 258.

[358] S. Li, D. Guo, Q. Sun, et al., “MAPK4 Silencing in Gastric Cancer Drives Liver Metastasis by Positive Feedback Between Cancer Cells and Macrophages,” Experimental & Molecular Medicine 55, no. 2 (2023): 457–469.

[359] K. Kumagai, T. Tanaka, K. Yamagata, N. Yokoyama, and K. Shimizu, “Liver Metastasis in Gastric Cancer With Particular Reference to Lymphatic Advancement,” Gastric Cancer 4, no. 3 (2001): 150–155.

[360] C. Zhao, G. Yuan, Y. Jiang, et al., “Capn4 Contributes to Tumor Invasion and Metastasis in Gastric Cancer via Activation of the Wnt/Beta-Catenin/MMP9 Signalling Pathways,” Experimental Cell Research 395, no. 2 (2020): 112220.

[361] Q. Ge, Y. Hu, J. He, et al., “Zic1 Suppresses Gastric Cancer Metastasis by Regulating Wnt/Beta-Catenin Signaling and Epithelial-Mesenchymal Transition,” FASEB Journal 34, no. 2 (2020): 2161–2172.

[362] A. Feng, X. Yuan, and X. Li, “MicroRNA-345 Inhibits Metastasis and Epithelial-Mesenchymal Transition of Gastric Cancer by Targeting FOXQ1,” Oncology Reports 38, no. 5 (2017): 2752–2760.

[363] E. Kucukkose, J. Laoukili, A. N. Gorelick, et al., “Lymphatic Invasion of Plakoglobin-Dependent Tumor Cell Clusters Drives Formation of Polyclonal Lung Metastases in Colon Cancer,” Gastroenterology 165, no. 2 (2023): 429–444 e15.

[364] A. Hoshino, B. Costa-Silva, T. L. Shen, et al., “Tumour Exosome Integrins Determine Organotropic Metastasis,” Nature 527, no. 7578 (2015): 329–335.

[365] Y. Gao, I. Bado, H. Wang, W. Zhang, J. M. Rosen, and X. H. Zhang, “Metastasis Organotropism: Redefining the Congenial Soil,” Developmental Cell 49, no. 3 (2019): 375–391.

[366] R. N. Kaplan, R. D. Riba, S. Zacharoulis, et al., “VEGFR1-Positive Haematopoietic Bone Marrow Progenitors Initiate the Pre-Metastatic Niche,” Nature 438, no. 7069 (2005): 820–827.

[367] S. Hiratsuka, K. Nakamura, S. Iwai, et al., “MMP9 Induction by Vascular Endothelial Growth Factor Receptor-1 Is Involved in Lung-Specific Metastasis,” Cancer Cell 2, no. 4 (2002): 289–300.

[368] B. Medeiros and A. L. Allan, “Molecular Mechanisms of Breast Cancer Metastasis to the Lung: Clinical and Experimental Perspectives,” International Journal of Molecular Sciences 20, no. 9 (2019): 2272.

[369] S. Hiratsuka, S. Goel, W. S. Kamoun, et al., “Endothelial Focal Adhesion Kinase Mediates Cancer Cell Homing to Discrete Regions of the Lungs via E-Selectin Up-Regulation,” PNAS 108, no. 9 (2011): 3725–3730.

[370] L. Wen, Y. Z. Li, J. Zhang, et al., “Clinical Analysis of Bone Metastasis of Gastric Cancer: Incidence, Clinicopathological Features and Survival,” Future Oncology (London, England) 15, no. 19 (2019): 2241–2249.

[371] J. Mikami, Y. Kimura, Y. Makari, et al., “Clinical Outcomes and Prognostic Factors for Gastric Cancer Patients With Bone Metastasis,” World Journal of Surgical Oncology 15, no. 1 (2017): 8.

[372] Y. J. Kim, S. H. Kim, J. W. Kim, et al., “Gastric Cancer With Initial Bone Metastasis: A Distinct Group of Diseases With Poor Prognosis,” European Journal of Cancer 50, no. 16 (2014): 2810–2821.

[373] X. H. Zhang, X. Jin, and S. Malladi, “Selection of Bone Metastasis Seeds by Mesenchymal Signals in the Primary Tumor Stroma,” Cell 154, no. 5 (2013): 1060–1073.

[374] Y. Shiozawa, E. A. Pedersen, A. M. Havens, et al., “Human Prostate Cancer Metastases Target the Hematopoietic Stem Cell Niche to Establish Footholds in Mouse Bone Marrow,” Journal of Clinical Investigation 121, no. 4 (2011): 1298–1312.

[375] L. D'Amico, M. A. Satolli, C. Mecca, et al., “Bone Metastases in Gastric Cancer Follow a RANKL-Independent Mechanism,” Oncology Reports 29, no. 4 (2013): 1453–1458.

[376] C. Leporini, M. Ammendola, I. Marech, et al., “Targeting Mast Cells in Gastric Cancer With Special Reference to Bone Metastases,” World Journal of Gastroenterology 21, no. 37 (2015): 10493–10501.

[377] D. F. Quail and J. A. Joyce, “Microenvironmental Regulation of Tumor Progression and Metastasis,” Nature Medicine 19, no. 11 (2013): 1423–1437.

[378] Y. Takahashi, K. R. Cleary, M. Mai, Y. Kitadai, C. D. Bucana, and L. M. Ellis, “Significance of Vessel Count and Vascular Endothelial Growth Factor and Its Receptor (KDR) in Intestinal-Type Gastric Cancer,” Clinical Cancer Research 2, no. 10 (1996): 1679–1684.

[379] Y. Kitadai, K. Haruma, K. Sumii, et al., “Expression of Interleukin-8 Correlates With Vascularity in Human Gastric Carcinomas,” American Journal of Pathology 152, no. 1 (1998): 93–100.

[380] D. Li, J. Bell, A. Brown, and C. L. Berry, “The Observation of Angiogenin and Basic Fibroblast Growth Factor Gene Expression in Human Colonic Adenocarcinomas, Gastric Adenocarcinomas, and Hepatocellular Carcinomas,” Journal of Pathology 172, no. 2 (1994): 171–175.

[381] Y. Takahashi, C. D. Bucana, Y. Akagi, et al., “Significance of Platelet-Derived Endothelial Cell Growth Factor in the Angiogenesis of Human Gastric Cancer,” Clinical Cancer Research 4, no. 2 (1998): 429–434.

[382] H. Mizuno, C. Sakamoto, K. Matsuda, et al., “Induction of Cyclooxygenase 2 in Gastric Mucosal Lesions and Its Inhibition by the Specific Antagonist Delays Healing in Mice,” Gastroenterology 112, no. 2 (1997): 387–397.

[383] T. Tsuji, R. Satoyoshi, N. Aiba, et al., “Agr2 Mediates Paracrine Effects on Stromal Fibroblasts That Promote Invasion by Gastric Signet-Ring Carcinoma Cells,” Cancer Research 75, no. 2 (2015): 356–366.

[384] M. Tanaka, S. Kuriyama, G. Itoh, et al., “Mesothelial Cells Create a Novel Tissue Niche That Facilitates Gastric Cancer Invasion,” Cancer Research 77, no. 3 (2017): 684–695.

[385] A. K. Zhu, Y. Q. Shan, J. Zhang, X. C. Liu, R. C. Ying, and W. C. Kong, “Exosomal NNMT From Peritoneum Lavage Fluid Promotes Peritoneal Metastasis in Gastric Cancer,” Kaohsiung Journal of Medical Sciences 37, no. 4 (2021): 305–313.

[386] B. Li, Y. Xia, J. Lv, et al., “miR-151a-3p-Rich Small Extracellular Vesicles Derived From Gastric Cancer Accelerate Liver Metastasis via Initiating a Hepatic Stemness-Enhancing Niche,” Oncogene 40, no. 43 (2021): 6180–6194.

[387] G. H. Kim and H. Y. Jung, “Endoscopic Resection of Gastric Cancer,” Gastrointestinal Endoscopy Clinics of North America 31, no. 3 (2021): 563–579.

[388] M. K. Back, H. S. Moon, I. S. Kwon, et al., “Analysis of Factors Associated With Local Recurrence After Endoscopic Resection of Gastric Epithelial Dysplasia: A Retrospective Study,” BMC Gastroenterology 20, no. 1 (2020): 148.

[389] Health Commission of the People's Republic of China N. National Guidelines for Diagnosis and Treatment of Gastric Cancer 2022 in China (English Version). Chinese Journal of Cancer Research = Chung-kuo yen cheng yen chiu 34, no. 3 (2022): 207–237.

[390] Japanese Gastric Cancer A. Japanese Gastric Cancer Treatment Guidelines 2021 (6th Edition). Gastric Cancer 26, no. 1 (2023): 1–25.

[391] J. L. Davis and R. T. Ripley, “Postgastrectomy Syndromes and Nutritional Considerations Following Gastric Surgery,” Surgical Clinics of North America 97, no. 2 (2017): 277–293.

[392] N. Hiki, S. Nunobe, T. Kubota, and X. Jiang, “Function-Preserving Gastrectomy for Early Gastric Cancer,” Annals of Surgical Oncology 20, no. 8 (2013): 2683–2692.

[393] S. Nunobe, M. Sasako, M. Saka, T. Fukagawa, H. Katai, and T. Sano, “Symptom Evaluation of Long-Term Postoperative Outcomes After Pylorus-Preserving Gastrectomy for Early Gastric Cancer,” Gastric Cancer 10, no. 3 (2007): 167–172.

[394] Japanese Gastric Cancer A. Japanese Gastric Cancer Treatment Guidelines 2014 (Ver. 4). Gastric Cancer 20, no. 1 (2017): 1–19.

[395] D. D'Ugo, S. Rausei, A. Biondi, and R. Persiani, “Preoperative Treatment and Surgery in Gastric Cancer: Friends or Foes?,” Lancet Oncology 10, no. 2 (2009): 191–195.

[396] D. Cunningham, W. H. Allum, S. P. Stenning, et al., “Perioperative Chemotherapy Versus Surgery Alone for Resectable Gastroesophageal Cancer,” New England Journal of Medicine 355, no. 1 (2006): 11–20.

[397] X. Wang, L. Zhao, H. Liu, et al., “A Phase II Study of a Modified FOLFOX6 Regimen as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer,” British Journal of Cancer 114, no. 12 (2016): 1326–1333.

[398] Y. W. Kim, M. J. Kim, K. W. Ryu, et al., “A Phase II Study of Perioperative S-1 Combined With Weekly Docetaxel in Patients With Locally Advanced Gastric Carcinoma: Clinical Outcomes and Clinicopathological and Pharmacogenetic Predictors for Survival,” Gastric Cancer 19, no. 2 (2016): 586–596.

[399] F. H. Wang, X. T. Zhang, Y. F. Li, et al., “The Chinese Society of Clinical Oncology (CSCO): Clinical Guidelines for the Diagnosis and Treatment of Gastric Cancer, 2021,” Cancer Communications (London) 41, no. 8 (2021): 747–795.

[400] J. Ji, L. Shen, Z. Li, et al., “Perioperative Chemotherapy of Oxaliplatin Combined With S-1 (SOX) Versus Postoperative Chemotherapy of SOX or Oxaliplatin With Capecitabine (XELOX) in Locally Advanced Gastric Adenocarcinoma With D2 Gastrectomy: A Randomized Phase III Trial (RESOLVE trial),” Annals of Oncology 30 (2019): v877.

[401] S. E. Al-Batran, N. Homann, C. Pauligk, et al., “Perioperative Chemotherapy With Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel Versus Fluorouracil or Capecitabine Plus Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma (FLOT4): A Randomised, Phase 2/3 Trial,” Lancet 393, no. 10184 (2019): 1948–1957.

[402] K. Sumpter, C. Harper-Wynne, D. Cunningham, et al., “Report of Two Protocol Planned Interim Analyses in a Randomised Multicentre Phase III Study Comparing Capecitabine With Fluorouracil and Oxaliplatin With Cisplatin in Patients With Advanced Oesophagogastric Cancer Receiving ECF,” British Journal of Cancer 92, no. 11 (2005): 1976–1983.

[403] Z. Y. Li, C. E. Koh, Z. D. Bu, et al., “Neoadjuvant Chemotherapy With FOLFOX: Improved Outcomes in Chinese Patients With Locally Advanced Gastric Cancer,” Journal of Surgical Oncology 105, no. 8 (2012): 793–799.

[404] M. Kochi, M. Fujii, N. Kanamori, et al., “Phase II Study of Neoadjuvant Chemotherapy With S-1 and CDDP in Patients With Lymph Node Metastatic Stage II or III Gastric Cancer,” American Journal of Clinical Oncology 40, no. 1 (2017): 17–21.

[405] T. Li and L. Chen, “Efficacy and Safety of SOX Regimen as Neoadjuvant Chemotherapy for Advanced Gastric Cancer,” Zhonghua wei chang wai ke za zhi = Chinese Journal of Gastrointestinal Surgery 14, no. 2 (2011): 104–106.

[406] L. Wang, M. Sun, J. Li, et al., “Intestinal Subtype as a Biomarker of Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Adenocarcinoma: Insights From a Prospective Phase II Trial,” Clinical Cancer Research 31, no. 1 (2025): 74–86.

[407] L. Wang, L. Wan, X. Chen, et al., “Reduced Intestinal-to-Diffuse Conversion and Immunosuppressive Responses Underlie Superiority of Neoadjuvant Immunochemotherapy in Gastric Adenocarcinoma,” MedComm 5, no. 11 (2024): e762.

[408] Z. Wang and T. Wang, “Mechanisms, Advances, and Challenges of Immunotherapy in Gastric Cancer,” Frontiers in Immunology 16 (2025): 1639487.

[409] Y. K. Kang, J. H. Yook, Y. K. Park, et al., “Phase III Randomized Study of Neoadjuvant Chemotherapy (CT) With Docetaxel(D), Oxaliplatin(O) and S-1(S) (DOS) Followed by Surgery and Adjuvant S-1, Vs Surgery and Adjuvant S-1, for Resectable Advanced Gastric Cancer (GC) (PRODIGY),” Annals of Oncology 30 (2019): v876–v877.

[410] M. Ychou, V. Boige, J. P. Pignon, et al., “Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial,” Journal of Clinical Oncology 29, no. 13 (2011): 1715–1721.

[411] C. Schuhmacher, S. Gretschel, F. Lordick, et al., “Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954,” Journal of Clinical Oncology 28, no. 35 (2010): 5210–5218.

[412] J. Stiekema, A. K. Trip, E. P. Jansen, et al., “Does Adjuvant Chemoradiotherapy Improve the Prognosis of Gastric Cancer After an r1 Resection? Results From a Dutch Cohort Study,” Annals of Surgical Oncology 22, no. 2 (2015): 581–588.

[413] Y. J. Bang, Y. W. Kim, H. K. Yang, et al., “Adjuvant Capecitabine and Oxaliplatin for Gastric Cancer After D2 Gastrectomy (CLASSIC): A Phase 3 Open-Label, Randomised Controlled Trial,” Lancet 379, no. 9813 (2012): 315–321.

[414] K. Yoshida, Y. Kodera, M. Kochi, et al., “Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients with Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial,” Journal of Clinical Oncology 37, no. 15 (2019): 1296–1304.

[415] E. C. Smyth, M. Verheij, W. Allum, D. Cunningham, A. Cervantes, and D. Arnold, “Gastric Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up,” Annals of Oncology 27, no. suppl 5 (2016): v38–v49.

[416] J. Lee, D. H. Lim, S. Kim, et al., “Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial,” Journal of Clinical Oncology 30, no. 3 (2012): 268–273.

[417] S. H. Park, D. Y. Zang, B. Han, et al., “ARTIST 2: Interim Results of a Phase III Trial Involving Adjuvant Chemotherapy and/or Chemoradiotherapy After D2-Gastrectomy in Stage II/III Gastric Cancer (GC),” Journal of Clinical Oncology 37, no. 15_suppl (2019): 4001–4001.

[418] C. Li, S. J. Oh, S. Kim, et al., “Macroscopic Borrmann Type as a Simple Prognostic Indicator in Patients With Advanced Gastric Cancer,” Oncology 77, no. 3–4 (2009): 197–204.

[419] K. Nakamura, H. Sugano, and K. Takagi, “Carcinoma of the Stomach in Incipient Phase: Its Histogenesis and Histological Appearances,” Gan 59, no. 3 (1968): 251–258.

[420] P. Lauren, “The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification,” Acta Pathologica et Microbiologica Scandinavica 64 (1965): 31–49.

[421] P. Morgagni, A. Gardini, D. Marrelli, et al., “Gastric Stump Carcinoma After Distal Subtotal Gastrectomy for Early Gastric Cancer: Experience of 541 Patients With Long-Term Follow-up,” American Journal of Surgery 209, no. 6 (2015): 1063–1068.

[422] D. G. Huntsman, F. Carneiro, F. R. Lewis, et al., “Early Gastric Cancer in Young, Asymptomatic Carriers of Germ-Line E-Cadherin Mutations,” New England Journal of Medicine 344, no. 25 (2001): 1904–1909.

[423] E. C. Smyth, “Chemotherapy for Resectable Microsatellite Instability-High Gastric Cancer?,” Lancet Oncology 21, no. 2 (2020): 204.

[424] C. S. Fuchs, K. Shitara, M. Di Bartolomeo, et al., “Ramucirumab With Cisplatin and Fluoropyrimidine as First-Line Therapy in Patients With Metastatic Gastric or Junctional Adenocarcinoma (RAINFALL): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial,” Lancet Oncology 20, no. 3 (2019): 420–435.

[425] K. Muro, E. Van Cutsem, Y. Narita, et al., “Pan-Asian Adapted ESMO Clinical Practice Guidelines for the Management of Patients With Metastatic Gastric Cancer: A JSMO-ESMO Initiative Endorsed by CSCO, KSMO, MOS, SSO and TOS,” Annals of Oncology 30, no. 1 (2019): 19–33.

[426] J. A. Ajani, T. A. D'Amico, and K. Almhanna, “Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology,” Journal of the National Comprehensive Cancer Network: JNCCN 14, no. 10 (2016): 1286–1312.

[427] Y. Yamada, N. Boku, J. Mizusawa, et al., “Docetaxel Plus Cisplatin and S-1 Versus Cisplatin and S-1 in Patients With Advanced Gastric Cancer (JCOG1013): An Open-Label, Phase 3, Randomised Controlled Trial,” Lancet Gastroenterology and Hepatology 4, no. 7 (2019): 501–510.

[428] L. L. Gunderson, R. B. Hoskins, A. C. Cohen, S. Kaufman, W. C. Wood, and R. W. Carey, “Combined Modality Treatment of Gastric Cancer,” International Journal of Radiation Oncology, Biology, Physics 9, no. 7 (1983): 965–975.

[429] Gastrointestinal Tumor Study Group. A Comparison of Combination Chemotherapy and Combined Modality Therapy for Locally Advanced Gastric Carcinoma. Cancer 49, no. 9 (1982): 1771–1777.

[430] A. D. Wagner, W. Grothe, J. Haerting, G. Kleber, A. Grothey, and W. E. Fleig, “Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data,” Journal of Clinical Oncology 24, no. 18 (2006): 2903–2909.

[431] F. Pietrantonio, M. Caporale, F. Morano, et al., “HER2 Loss in HER2-Positive Gastric or Gastroesophageal Cancer After Trastuzumab Therapy: Implication for Further Clinical Research,” International Journal of Cancer 139, no. 12 (2016): 2859–2864.

[432] X. Paoletti, K. Oba, T. Burzykowski, et al., “Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer: A Meta-Analysis,” JAMA 303, no. 17 (2010): 1729–1737.

[433] J. Tabernero, P. M. Hoff, L. Shen, et al., “Pertuzumab, Trastuzumab, and Chemotherapy in HER2-Positive Gastric/Gastroesophageal Junction Cancer: End-of-Study Analysis of the JACOB Phase III Randomized Clinical Trial,” Gastric Cancer 26, no. 1 (2023): 123–131.

[434] M. Tanaka, J. Shibahara, N. Fukushima, et al., “Claudin-18 Is an Early-Stage Marker of Pancreatic Carcinogenesis,” Journal of Histochemistry and Cytochemistry 59, no. 10 (2011): 942–952.

[435] Y. Kubota and K. Shitara, “Zolbetuximab for Claudin18.2-Positive Gastric or Gastroesophageal Junction Cancer,” Therapeutic Advances in Medical Oncology 16 (2024): 17588359231217967.

[436] N. Deng, L. K. Goh, H. Wang, et al., “A Comprehensive Survey of Genomic Alterations in Gastric Cancer Reveals Systematic Patterns of Molecular Exclusivity and Co-Occurrence Among Distinct Therapeutic Targets,” Gut 61, no. 5 (2012): 673–684.

[437] X. Su, P. Zhan, P. R. Gavine, et al., “FGFR2 Amplification Has Prognostic Significance in Gastric Cancer: Results From a Large International Multicentre Study,” British Journal of Cancer 110, no. 4 (2014): 967–975.

[438] Y. K. Kang, S. Qin, K. W. Lee, et al., “Bemarituzumab Plus mFOLFOX6 as First-Line Treatment in East Asian Patients With FGFR2b-Overexpressing Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer: Subgroup of FIGHT Final Analysis,” Gastric Cancer 27, no. 5 (2024): 1046–1057.

[439] D. V. T. Catenacci, D. Rasco, J. Lee, et al., “Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma,” Journal of Clinical Oncology 38, no. 21 (2020): 2418–2426.

[440] Y. K. Kang, N. Boku, T. Satoh, et al., “Nivolumab in Patients With Advanced Gastric or Gastro-Oesophageal Junction Cancer Refractory to, or Intolerant of, at Least Two Previous Chemotherapy Regimens (ONO-4538-12, ATTRACTION-2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial,” Lancet 390, no. 10111 (2017): 2461–2471.

[441] M. H. Moehler, Y. Y. Janjigian, A. Adenis, et al., “CheckMate 649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab (Nivo) + Ipilimumab (Ipi) or Nivo + Chemotherapy (CTX) Vs CTX Alone in Pts With Previously Untreated Advanced (Adv) Gastric (G) or Gastroesophageal Junction (GEJ) Cancer,” Journal of Clinical Oncology 35, no. 15_suppl (2017): TPS4132–TPS4132.

[442] M. Moehler, K. Shitara, M. Garrido, et al., “LBA6_PR Nivolumab (Nivo) Plus Chemotherapy (Chemo) Versus Chemo as First-Line (1L) Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer (GC/GEJC)/Esophageal Adenocarcinoma (EAC): First Results of the CheckMate 649 Study,” Annals of Oncology 31 (2020): S1191.

[443] S. J. Keam, “Cadonilimab: First Approval,” Drugs 82, no. 12 (2022): 1333–1339.

[444] E. Smyth, M. Knodler, A. Giraut, et al., “VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy with High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study,” Frontiers in Oncology 9 (2019): 1320.

[445] P. Li, X. Zhang, L. Gu, J. Zhou, and D. Deng, “P16 Methylation Increases the Sensitivity of Cancer Cells to the CDK4/6 Inhibitor Palbociclib,” PLoS ONE 14, no. 10 (2019): e0223084.

[446] T. Seidlitz, S. R. Merker, A. Rothe, et al., “Human Gastric Cancer Modelling Using Organoids,” Gut 68, no. 2 (2019): 207–217.

[447] T. B. Karasic, M. H. O'Hara, U. R. Teitelbaum, et al., “Phase II Trial of Palbociclib in Patients With Advanced Esophageal or Gastric Cancer,” Oncologist 25, no. 12 (2020): e1864–e1868.

[448] M. Alvarez-Fernandez and M. Malumbres, “Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition,” Cancer Cell 37, no. 4 (2020): 514–529.

[449] S. Peuget, X. Zhou, and G. Selivanova, “Translating p53-Based Therapies for Cancer Into the Clinic,” Nature Reviews Cancer 24, no. 3 (2024): 192–215.

[450] C. H. June, R. S. O'Connor, O. U. Kawalekar, S. Ghassemi, and M. C. Milone, “CAR T Cell Immunotherapy for Human Cancer,” Science 359, no. 6382 (2018): 1361–1365.

[451] Y. Song, C. Tong, Y. Wang, et al., “Effective and Persistent Antitumor Activity of HER2-Directed CAR-T Cells Against Gastric Cancer Cells In Vitro and Xenotransplanted Tumors In Vivo,” Protein Cell 9, no. 10 (2018): 867–878.

[452] H. Jiang, Z. Shi, P. Wang, et al., “Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer,” Journal of the National Cancer Institute 111, no. 4 (2019): 409–418.

[453] J. Lv, R. Zhao, D. Wu, et al., “Mesothelin Is a Target of Chimeric Antigen Receptor T Cells for Treating Gastric Cancer,” Journal of Hematology & Oncology 12, no. 1 (2019): 18.

[454] K. Tao, M. He, F. Tao, et al., “Development of NKG2D-Based Chimeric Antigen Receptor-T Cells for Gastric Cancer Treatment,” Cancer Chemotheraphy and Pharmacology 82, no. 5 (2018): 815–827.

[455] D. Bębnowska, E. Grywalska, P. Niedźwiedzka-Rystwej, et al., “CAR-T Cell Therapy – An Overview of Targets in Gastric Cancer,” Journal of Clinical Medicine 9, no. 6 (2020): 1894.

[456] R. M. Young, N. W. Engel, U. Uslu, N. Wellhausen, and C. H. June, “Next-Generation CAR T-Cell Therapies,” Cancer Discovery 12, no. 7 (2022): 1625–1633.

[457] C. R. Good, M. A. Aznar, S. Kuramitsu, et al., “An NK-Like CAR T Cell Transition in CAR T Cell Dysfunction,” Cell 184, no. 25 (2021): 6081–6100.

[458] R. C. Lynn, E. W. Weber, E. Sotillo, et al., “c-Jun Overexpression in CAR T Cells Induces Exhaustion Resistance,” Nature 576, no. 7786 (2019): 293–300.

[459] A. Hirayama, T. Tanaka, T. Ohishi, et al., “Therapeutic Potential of an Anti-CD44v6 Monoclonal Antibody in Xenograft Models of Colorectal and Gastric Cancer,” Cells 14, no. 23 (2025): 1873.

[460] X. Hao, J. Liu, H. Li, et al., “Abstract 4723: Development and Preclinical Activity of BSI-721, a Novel Antibody-Drug Conjugate (ADC) Targeting Cadherin 17 (CDH17) in Gastrointestinal Cancers,” Cancer Research 85, no. 8_suppl_1 (2025): 4723–4723.

[461] G. Mu, F. Zhou, Z. Zha, et al., “Abstract 2863: TAVO307, a Novel ADC Targeting CDH17, for the Therapy of Gastrointestinal Cancers,” Cancer Research 85, no. 8_suppl_1 (2025): 2863–2863.

[462] Z. Li, C. Shang, Z. Han, et al., “Abstract 2617: BCG022, a Novel HER3 × MET Bispecific Antibody-Drug Conjugate (bsADC), Demonstrates Promising Anti-Tumor Efficacy,” Cancer Research 84, no. 6_suppl (2024): 2617–2617.

[463] L. Ma, N. Zhang, C. Shang, and Y. Yang, “Abstract 4793: BCG033: A First-in-Class PTK7×TROP2 Bispecific ADC Demonstrating Potent and Broad Efficacy in Various Preclinical Models,” Cancer Research 85, no. 8_suppl_1 (2025): 4793–4793.

[464] L. Zheng, Y. Wang, Z. Jiang, et al., “Discovery of LC-SF-14, a Selective Dual Inhibitor of SHP2 and FGFR for the Treatment of FGFR2-Driven Gastric Cancer,” European Journal of Medicinal Chemistry 294 (2025): 117745.

[465] Z. Feng, S. Wang, S. Yu, C. Qu, B. Chu, and Z. Qian, “Synthesis and Identification of a Selective FGFR2 Degrader With Potent Antiproliferative Effects in Gastric Cancer,” European Journal of Medicinal Chemistry 277 (2024): 116780.

[466] L. Zhao, H. Niu, Y. Liu, et al., “LOX Inhibition Downregulates MMP-2 and MMP-9 in Gastric Cancer Tissues and Cells,” Journal of Cancer 10, no. 26 (2019): 6481–6490.

[467] S. Miyoshi, M. Kudo, K. Shitara, M. Yamauchi, T. Doi, and Y. Matsumura, “TGF-β Inhibitor LY2157299 (Galunisertib) in Combination With Standard Chemotherapy and Inhibition of Signaling to pSmad and EMT and Suppression of Tumor Growth in Gastric Cancer,” Cells 34, no. 4_suppl (2016): 50–50.

[468] Z. Liu, H. Chen, N. Ta, et al., “Anti-CD47 Antibody Enhances the Efficacy of Chemotherapy in Patients With Gastric Cancer Liver Metastasis,” Journal of Cancer 14, no. 3 (2023): 350–359.

[469] Y. Y. Janjigian, A. Kawazoe, P. Yanez, et al., “The KEYNOTE-811 Trial of Dual PD-1 and HER2 Blockade in HER2-Positive Gastric Cancer,” Nature 600, no. 7890 (2021): 727–730.

[470] S. J. Klempner, K. W. Lee, K. Shitara, et al., “ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients With Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma,” Clinical Cancer Research 29, no. 19 (2023): 3882–3891.

[471] Y. J. Bang, R. H. Xu, K. Chin, et al., “Olaparib in Combination With paclitaxel in Patients With Advanced Gastric Cancer Who Have Progressed Following First-Line Therapy (GOLD): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial,” Lancet Oncology 18, no. 12 (2017): 1637–1651.

[472] Z. A. Wainberg, Y. K. Kang, K. W. Lee, et al., “Bemarituzumab as First-Line Treatment for Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Final Analysis of the Randomized Phase 2 FIGHT Trial,” Gastric Cancer 27, no. 3 (2024): 558–570.

[473] Z. A. Wainberg, P. C. Enzinger, Y. K. Kang, et al., “Bemarituzumab in Patients With FGFR2b-Selected Gastric or Gastro-Oesophageal Junction Adenocarcinoma (FIGHT): A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Study,” Lancet Oncology 23, no. 11 (2022): 1430–1440.

[474] Y. Y. Janjigian, K. Shitara, M. Moehler, et al., “First-Line Nivolumab Plus Chemotherapy Versus Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial,” Lancet 398, no. 10294 (2021): 27–40.

[475] T. W. Kim, P. L. Bedard, P. LoRusso, et al., “Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial,” JAMA Oncology 9, no. 11 (2023): 1574–1582.

[476] B. C. Cho, D. R. Abreu, M. Hussein, et al., “Tiragolumab Plus Atezolizumab Versus Placebo Plus Atezolizumab as a First-Line Treatment for PD-L1-Selected Non-Small-Cell Lung Cancer (CITYSCAPE): Primary and Follow-Up Analyses of a Randomised, Double-Blind, Phase 2 Study,” Lancet Oncology 23, no. 6 (2022): 781–792.

[477] J. Xu, H. Jiang, Y. Pan, et al., “Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial,” JAMA 330, no. 21 (2023): 2064–2074.

[478] K. Shitara, J. A. Ajani, M. Moehler, et al., “Nivolumab Plus Chemotherapy or Ipilimumab in Gastro-Oesophageal Cancer,” Nature 603, no. 7903 (2022): 942–948.

[479] L. Vitale, M. Murphy, C. Xia, et al., “798 CDX-585, a Bispecific Antibody With Dual Targeting of ILT4 and PD-1 Checkpoint Pathways,” Journal for ImmunoTherapy of Cancer 9, no. suppl 2 (2021): A833–A833.

[480] L. An, R. Yu, Y. Han, and Z. Zhou, “Decoding the Intercellular Communication Network During Tumorigenesis,” Cancer Biology & Medicine 19, no. 3 (2021): 265–272.

[481] J. Su, Y. Song, Z. Zhu, et al., “Cell–Cell Communication: New Insights and Clinical Implications,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 196.

[482] M. Monje, J. C. Borniger, and N. J. D'Silva, “Roadmap for the Emerging Field of Cancer Neuroscience,” Cell 181, no. 2 (2020): 219–222.

[483] N. Li, H. Tong, W. Hou, et al., “Neural-Cancer Crosstalk: Reciprocal Molecular Circuits Driving Gastric Tumorigenesis and Emerging Therapeutic Opportunities,” Cancer Letters 616 (2025): 217589.

[484] N. Erin, G. V. Shurin, J. H. Baraldi, and M. R. Shurin, “Regulation of Carcinogenesis by Sensory Neurons and Neuromediators,” Cancers (Basel) 14, no. 9 (2022): 2333.

[485] R. A. Flynn, K. Pedram, S. A. Malaker, et al., “Small RNAs Are Modified With N-Glycans and Displayed on the Surface of Living Cells,” Cell 184, no. 12 (2021): 3109–3124 e22.

[486] V. R. Graziano, J. Porat, M. D. Ah Kioon, et al., “RNA N-Glycosylation Enables Immune Evasion and Homeostatic Efferocytosis,” Nature 645, no. 8081 (2025): 784–792.

[487] N. Zhang, W. Tang, L. Torres, et al., “Cell Surface RNAs Control Neutrophil Recruitment,” Cell 187, no. 4 (2024): 846–860.

[488] J. Wang, L. Du, and X. Chen, “Adenosine Signaling: Optimal Target for Gastric Cancer Immunotherapy,” Frontiers in Immunology 13 (2022): 1027838.

[489] Z. Q. Zheng, C. R. Zhong, C. Z. Wei, et al., “Hyperactivation of mTOR/eIF4E Signaling Pathway Promotes the Production of Tryptophan-to-Phenylalanine Substitutants in EBV-Positive Gastric Cancer,” Advanced Science (Weinheim) 11, no. 35 (2024): e2402284.

[490] M. Koh, T. Takahashi, Y. Kurokawa, et al., “Propranolol Suppresses Gastric Cancer Cell Growth by Regulating Proliferation and Apoptosis,” Gastric Cancer 24, no. 5 (2021): 1037–1049.

[491] S. H. Sohn, H. J. Sul, B. J. Kim, H. S. Kim, and D. Y. Zang, “Entrectinib Induces Apoptosis and Inhibits the Epithelial-Mesenchymal Transition in Gastric Cancer With NTRK Overexpression,” International Journal of Molecular Sciences 23, no. 1 (2021): 395.

[492] K. Fu, A. H. K. Cheung, C. C. Wong, et al., “Streptococcus anginosus Promotes Gastric Inflammation, Atrophy, and Tumorigenesis in Mice,” Cell 187, no. 4 (2024): 882–896.e17.

[493] C. B. Zhou, S. Y. Pan, and P. Jin, “Fecal Signatures of Streptococcus anginosus and Streptococcus constellatus for Noninvasive Screening and Early Warning of Gastric Cancer,” Gastroenterology 162, no. 7 (2022): 1933–1947.e18.

[494] L. Yuan, L. Pan, Y. Wang, et al., “Characterization of the Landscape of the Intratumoral Microbiota Reveals That Streptococcus anginosus Increases the Risk of Gastric Cancer Initiation and Progression,” Cell Discovery 10, no. 1 (2024): 117.

[495] A. Fu, B. Yao, T. Dong, et al., “Tumor-Resident Intracellular Microbiota Promotes Metastatic Colonization in Breast Cancer,” Cell 185, no. 8 (2022): 1356–1372.e26.

[496] N. N. Liu, C. X. Yi, L. Q. Wei, et al., “The Intratumor Mycobiome Promotes Lung Cancer Progression via Myeloid-Derived Suppressor Cells,” Cancer Cell 41, no. 11 (2023): 1927–1944.e9.

[497] H. Wu, X. Leng, Q. Liu, et al., “Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma,” Cancer Research 83, no. 18 (2023): 3131–3144.

[498] R. Palieri, M. De Luca, F. Balestra, et al., “Liquid Biopsy in Gastrointestinal Oncology: Clinical Applications and Translational Integration of ctDNA, CTCs, and sEVs,” Oncology Reviews 19 (2025): 1702932.

[499] S. Li, M. Xu, Y. Meng, et al., “The Application of the Combination Between Artificial Intelligence and Endoscopy in Gastrointestinal Tumors,” MEDCOMM—Oncology 3, no. 4 (2024): e91.

[500] W. Huang, X. Wang, R. Zhong, et al., “Multimodal Radiopathomics Signature for Prediction of Response to Immunotherapy-Based Combination Therapy in Gastric Cancer Using Interpretable Machine Learning,” Cancer Letters 631 (2025): 217930.

[501] C. Wang, W. Liu, D. Ai, and X. Liu, “ProMMF_Kron: A Multimodal Deep Learning Model for Immunotherapy Response Prediction in Stomach Adenocarcinoma,” Frontiers in Immunology 17 (2026): 1602846.

[502] D. Paul, G. Sanap, S. Shenoy, D. Kalyane, K. Kalia, and R. K. Tekade, “Artificial Intelligence in Drug Discovery and Development,” Drug Discovery Today 26, no. 1 (2021): 80–93.

[503] Q. Wang, Y. Ni, S. Lu, et al., “Multi-Dimensional Omics Integrated Machine Learning Framework Identifies Macrophage-Fibroblast-Tumor Co-Infiltration Patterns to Predict Prognosis in Gastric Cancer,” NPJ Digital Medicine 9, no. 1 (2025): 10.

[504] C. Sadee, S. Testa, T. Barba, et al., “Medical Digital Twins: Enabling Precision Medicine and Medical Artificial Intelligence,” Lancet Digit Health 7, no. 7 (2025): 100864.

[505] G. Che, J. Yin, W. Wang, et al., “Circumventing Drug Resistance in Gastric Cancer: A Spatial Multi-Omics Exploration of Chemo and Immuno-Therapeutic Response Dynamics,” Drug Resistance Updates 74 (2024): 101080.

[506] A. Ebigbo, H. Messmann, and S. H. Lee, “Artificial Intelligence Applications in Image-Based Diagnosis of Early Esophageal and Gastric Neoplasms,” Gastroenterology 169, no. 3 (2025): 396-415 e2.

[507] N. Li, J. Yang, X. Li, Y. Shi, and K. Wang, “Accuracy of Artificial Intelligence-Assisted Endoscopy in the Diagnosis of Gastric Intestinal Metaplasia: A Systematic Review and Meta-Analysis,” PLoS ONE 19, no. 5 (2024): e0303421.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.